<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta http-equiv="refresh" content="86400">
    <style>
        body {
            font-family: Arial, sans-serif;
            line-height: 1.6;
            max-width: 1200px;
            margin: 0 auto;
            padding: 20px;
            background-color: #f5f5f5;
        }
        h1 {
            color: #333;
            text-align: center;
            margin-bottom: 30px;
        }
        .news-grid {
            display: grid;
            grid-template-columns: repeat(auto-fill, minmax(350px, 1fr));
            gap: 20px;
        }
        .news-card {
            background-color: white;
            border-radius: 8px;
            box-shadow: 0 2px 5px rgba(0,0,0,0.1);
            padding: 20px;
            transition: transform 0.2s ease;
        }
        .news-card:hover {
            transform: translateY(-5px);
            box-shadow: 0 5px 15px rgba(0,0,0,0.1);
        }
        .news-title {
            font-size: 18px;
            margin-top: 0;
        }
        .news-source {
            color: #666;
            font-size: 14px;
            margin-bottom: 10px;
        }
        .company-tag {
            display: inline-block;
            background-color: #e0f7fa;
            color: #006064;
            padding: 3px 8px;
            border-radius: 4px;
            font-size: 12px;
            font-weight: bold;
        }
        .news-date {
            color: #888;
            font-size: 12px;
            margin-top: 10px;
        }
        .timestamp {
            text-align: left;
            color: #000000;
            font-size: 24px;
            margin-top: 0px;
        }
        a {
            color: #0066cc;
            text-decoration: none;
        }
        a:hover {
            text-decoration: underline;
        }
        .header {
            display: flex;
            justify-content: space-between;
            align-items: center;
            margin-bottom: 20px;
        }
        /* Image thumbnail styles */
        .news-image {
            margin-bottom: 15px;
            max-height: 180px;
            overflow: hidden;
            border-radius: 6px;
        }
        .news-image img {
            width: 100%;
            height: 180px;
            object-fit: cover;
            display: block;
            transition: transform 0.3s ease;
        }
        .news-card:hover .news-image img {
            transform: scale(1.05);
        }
        
        /* Chatbot styles */
        .chatbot-container {
            position: fixed;
            top: 20px; /* Changed from bottom to top */
            right: 20px;
            width: 350px;
            height: calc(100vh - 40px); /* Changed to take up almost full viewport height */
            background-color: white;
            border-radius: 10px;
            box-shadow: 0 5px 25px rgba(0,0,0,0.2);
            display: flex;
            flex-direction: column;
            z-index: 1000;
            transition: transform 0.3s ease, opacity 0.3s ease;
            transform: translateX(110%); /* Changed from translateY to translateX */
            opacity: 0;
            overflow: hidden; /* Added to ensure no overflow */
        }
        
        .chatbot-container.active {
            transform: translateX(0); /* Changed from translateY to translateX */
            opacity: 1;
        }
        
        .chatbot-header {
            background-color: #0066cc;
            color: white;
            padding: 15px;
            border-radius: 10px 10px 0 0;
            display: flex;
            justify-content: space-between;
            align-items: center;
        }
        
        .chatbot-title {
            font-weight: bold;
            margin: 0;
        }
        
        .chatbot-messages {
            flex: 1;
            padding: 15px;
            overflow-y: auto;
            display: flex;
            flex-direction: column;
            max-height: calc(100vh - 140px); /* Added to ensure scrolling works properly */
        }
        
        .message {
            margin-bottom: 10px;
            max-width: 80%;
            padding: 10px 15px;
            border-radius: 18px;
            line-height: 1.4;
        }
        
        .user-message {
            align-self: flex-end;
            background-color: #0066cc;
            color: white;
        }
        
        .bot-message {
            align-self: flex-start;
            background-color: #f1f1f1;
        }
        
        .chatbot-input {
            display: flex;
            padding: 10px;
            border-top: 1px solid #e0e0e0;
        }
        
        .chatbot-input input {
            flex: 1;
            padding: 10px 15px;
            border: 1px solid #ddd;
            border-radius: 20px;
            outline: none;
        }
        
        .chatbot-input button {
            background-color: #0066cc;
            color: white;
            border: none;
            border-radius: 20px;
            padding: 10px 15px;
            margin-left: 10px;
            cursor: pointer;
        }
        
        .chat-toggle-button {
            position: fixed;
            bottom: 20px;
            right: 20px;
            width: 60px;
            height: 60px;
            background-color: #0066cc;
            color: white;
            border: none;
            border-radius: 50%;
            display: none; /* Changed from flex to none to hide initially */
            justify-content: center;
            align-items: center;
            font-size: 24px;
            cursor: pointer;
            box-shadow: 0 4px 8px rgba(0,0,0,0.2);
            z-index: 1001;
            opacity: 1;
            visibility: visible;
        }
        
        /* Adding a pulsing animation to make the chat button more noticeable */
        @keyframes pulse {
            0% { transform: scale(1); box-shadow: 0 4px 8px rgba(0,0,0,0.2); }
            50% { transform: scale(1.05); box-shadow: 0 8px 16px rgba(0,0,0,0.3); }
            100% { transform: scale(1); box-shadow: 0 4px 8px rgba(0,0,0,0.2); }
        }
        
        .chat-toggle-button {
            animation: pulse 2s infinite;
        }
        
        .chat-toggle-button:hover {
            background-color: #0055bb;
        }

        .source-citation {
            font-size: 12px;
            color: #666;
            margin-top: 5px;
            font-style: italic;
        }
    </style>
</head>
<body>
    <div class="news-grid">

    <div class="news-card">
        <span class="company-tag">Unaliwear</span>
        
        <h3 class="news-title"><a href="https://www.forbes.com/health/medical-alert-systems/unaliwear-review/" target="_blank">UnaliWear Medical Alert Watch Review In 2025</a></h3>
        <div class="news-source">Forbes</div>
        <p>Our editors also may be in touch with follow-up questions. The water-resistant UnaliWear Kanega Watch is a medical alert device that provides automatic fall detection, 24/7 monitoring and ...</p>
        <div class="news-date">2024-02-15</div>
    </div>
    
    <div class="news-card">
        <span class="company-tag">Unaliwear</span>
        
        <h3 class="news-title"><a href="https://www.consumeraffairs.com/medical-alert-systems/unaliwear-kanega-watch.html" target="_blank">UnaliWear Kanega Watch Reviews</a></h3>
        <div class="news-source">ConsumerAffairs</div>
        <p>The UnaliWear Kanega Watch is a more discreet alternative to traditional medical alert devices. The watch weighs 49 grams (about 1.7 ounces). It&#x27;s 1.6 inches in diameter and 0.5 inches thick.</p>
        <div class="news-date">2025-05-13</div>
    </div>
    
    <div class="news-card">
        <span class="company-tag">BrainCheck</span>
        
        <h3 class="news-title"><a href="https://finance.yahoo.com/news/braincheck-expands-first-end-end-130000828.html" target="_blank">BrainCheck Expands First End-to-End Solution for Cognitive Care</a></h3>
        <div class="news-source">Yahoo Finance</div>
        <p>Company introduces next generation of its comprehensive platform and 3-minute screening tool at Clinical Trials on Alzheimer&#x27;s Disease (CTAD) conference New research supporting BrainCheck platform ...</p>
        <div class="news-date">2023-10-24</div>
    </div>
    
    <div class="news-card">
        <span class="company-tag">BrainCheck</span>
        
        <h3 class="news-title"><a href="https://www.wkrn.com/business/press-releases/cision/20240306DA53947/braincheck-secures-15-million-to-fuel-expansion-and-adoption-of-its-next-generation-digital-cognitive-assessment-and-care-planning-platform/" target="_blank">BrainCheck Secures $15 Million to Fuel Expansion and Adoption of its Next Generation Digital Cognitive Assessment and Care Planning Platform</a></h3>
        <div class="news-source">WKRN-TV</div>
        <p>New financing round, led by Next Coast Ventures, S3 Ventures, and UPMC Enterprises, positions Company for continued growth, innovation, and integration BrainCheck expands Board of Directors ...</p>
        <div class="news-date">2024-03-06</div>
    </div>
    
    <div class="news-card">
        <span class="company-tag">Dermala</span>
        
        <h3 class="news-title"><a href="https://markets.businessinsider.com/news/stocks/dermala-a-consumer-dermatology-company-announces-issuance-of-the-second-u-s-patent-covering-the-use-of-novel-human-microbiome-technology-for-treating-acne-vulgaris-1030899083" target="_blank">DERMALA, A Consumer Dermatology Company, Announces Issuance of the Second U.S. Patent Covering the Use of Novel Human Microbiome Technology for Treating Acne Vulgaris</a></h3>
        <div class="news-source">Business Insider</div>
        <p>SAN DIEGO, Oct. 26, 2021 /PRNewswire/ -- DERMALA, a consumer dermatology company developing novel, personalized, microbiome-powered solutions for chronic skin conditions, announced today the ...</p>
        <div class="news-date">2021-10-26</div>
    </div>
    
    <div class="news-card">
        <span class="company-tag">Dermala</span>
        
        <h3 class="news-title"><a href="https://www.businesswire.com/news/home/20201109005312/en/DERMALA-Announces-6.73-Million-Series-A-Financing-to-Expand-and-Scale-Companyâ€™s-Personalized-Microbiome-Based-Solutions-for-Acne-and-Other-Skin-Conditions" target="_blank">DERMALA Announces $6.73 Million Series A Financing to Expand and Scale Company&#x27;s Personalized Microbiome-Based Solutions for Acne and Other Skin Conditions</a></h3>
        <div class="news-source">Business Wire</div>
        <p>SAN DIEGO--(BUSINESS WIRE)--DERMALA, Inc., a consumer dermatology company developing novel, personalized, microbiome-based solutions for acne and other skin conditions, announced today that it has ...</p>
        <div class="news-date">2020-11-09</div>
    </div>
    
    <div class="news-card">
        <span class="company-tag">Oralucent</span>
        
        <h3 class="news-title">No news</h3>
        <div class="news-source"></div>
        <p></p>
        
    </div>
    
    <div class="news-card">
        <span class="company-tag">Flowly</span>
        
        <h3 class="news-title"><a href="https://www.fiercehealthcare.com/digital-health/relaxation-app-vr-startup-flowly-rolls-out-program-providers" target="_blank">Flowly, VR-enabled app to manage chronic pain and stress, rolls out program for providers</a></h3>
        <div class="news-source">Fierce Healthcare</div>
        <p>Flowly, an app for autonomic nervous system regulation, has launched a program for providers, the company has shared exclusively with Fierce Healthcare. Through the program, providers will receive ...</p>
        <div class="news-date">2023-03-13</div>
    </div>
    
    <div class="news-card">
        <span class="company-tag">Flowly</span>
        
        <h3 class="news-title"><a href="https://www.businesswire.com/news/home/20200609005289/en/Flowly-Offers-Relief-to-100-Million-Americans-Living-with-Chronic-Pain-and-Anxiety" target="_blank">Flowly Offers Relief to 100 Million Americans Living with Chronic Pain and Anxiety</a></h3>
        <div class="news-source">Business Wire</div>
        <p>LOS ANGELES--(BUSINESS WIRE)--Flowly today officially launched its interactive mobile app to address chronic pain and anxiety. The platform offers immersive experiences in beautiful and peaceful ...</p>
        <div class="news-date">2020-06-09</div>
    </div>
    
    <div class="news-card">
        <span class="company-tag">Rosy Wellness</span>
        <div class="news-image"><img src="https://s.yimg.com/ny/api/res/1.2/IIZPSsivGxnOci.U38XKUA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD05MDU-/https://media.zenfs.com/en/globenewswire.com/bb1d1625b47c6718857f64e784f0f2e4" alt="DarÃ© Bioscience and Rosy Wellness Announce Strategic Collaboration to Educate and Market DarÃ©&#x27;s DARE to PLAY Sildenafil Cream"></div>
        <h3 class="news-title"><a href="https://finance.yahoo.com/news/dar-bioscience-rosy-wellness-announce-120000637.html" target="_blank">DarÃ© Bioscience and Rosy Wellness Announce Strategic Collaboration to Educate and Market DarÃ©&#x27;s DARE to PLAY Sildenafil Cream</a></h3>
        <div class="news-source">Yahoo Finance</div>
        <p>Collaboration will leverage Rosy Wellness&#x27; extensive reach and community of over 250,000 women Rosy Wellness is a multi-award winning app recommended by 8,000+ healthcare professionals DarÃ© expects to start recording revenue in the 4th quarter this year SAN DIEGO,</p>
        <div class="news-date">2025-06-04</div>
    </div>
    
    <div class="news-card">
        <span class="company-tag">Rosy Wellness</span>
        
        <h3 class="news-title"><a href="https://www.investing.com/news/company-news/dare-bioscience-partners-with-rosy-wellness-for-new-womens-health-cream-93CH-4080414" target="_blank">DarÃ© Bioscience partners with Rosy Wellness for new women&#x27;s health cream</a></h3>
        <div class="news-source">Investing</div>
        <p>Rosy Wellness, with its community of over 250,000 women and recommendation by more than 8,000 healthcare professionals, will leverage its digital reach and content-driven model to support the launch.</p>
        <div class="news-date">2025-06-04</div>
    </div>
    
    <div class="news-card">
        <span class="company-tag">De Oro Devices</span>
        
        <h3 class="news-title"><a href="https://finance.yahoo.com/news/oro-devices-names-cori-lathan-220500791.html" target="_blank">De Oro Devices Names Cori Lathan, PhD, as New CEO</a></h3>
        <div class="news-source">Yahoo Finance</div>
        <p>Dr. Lathan joins De Oro Devices from her previous role as CEO at AnthroTronix, where she successfully invented, developed, and commercialized medical technology for over 20 years before leading ...</p>
        <div class="news-date">2024-01-18</div>
    </div>
    
    <div class="news-card">
        <span class="company-tag">De Oro Devices</span>
        
        <h3 class="news-title"><a href="https://abc30.com/parkinsons-disease-nexstride-device-de-oro-devices-clovis-veteran-able-to-walk/12728394/" target="_blank">New device helps Clovis veteran with Parkinson&#x27;s walk again</a></h3>
        <div class="news-source">ABC30 Action News</div>
        <p>CLOVIS, Calif. (KFSN) -- The simple act of walking can be challenging for those living with Parkinson&#x27;s disease, which affects movement. However, a Clovis veteran is now on the move with the help ...</p>
        <div class="news-date">2023-01-25</div>
    </div>
    
    <div class="news-card">
        <span class="company-tag">Partum Health</span>
        
        <h3 class="news-title"><a href="https://medcitynews.com/tag/partum-health/" target="_blank">Partum Health</a></h3>
        <div class="news-source">MedCity News</div>
        <p>Partum Health, a maternal health startup, recently won the consumer/employer track of the MedCity News INVEST Pitch Perfect contest. The direct-to-consumer company supports families during ...</p>
        <div class="news-date">2023-06-04</div>
    </div>
    
    <div class="news-card">
        <span class="company-tag">Partum Health</span>
        
        <h3 class="news-title"><a href="https://medcitynews.com/2023/06/maternal-healthcare-postpartum-birth-fertility/" target="_blank">INVEST Pitch Perfect Spotlight: How Partum Health Is Working To Transform Maternal Healthcare</a></h3>
        <div class="news-source">MedCity News</div>
        <p>Meghan Doyle, co-founder and CEO of Partum Health, was working at a consulting firm in the healthcare sector when she first became a mom. It was during this time that she realized how confusing ...</p>
        <div class="news-date">2023-06-03</div>
    </div>
    
    <div class="news-card">
        <span class="company-tag">Fort Health</span>
        
        <h3 class="news-title"><a href="https://www.everydayhealth.com/emotional-health/fort-health-review/" target="_blank">At Fort Health, My Teen Finally Found a Therapist He Doesn&#x27;t Hate</a></h3>
        <div class="news-source">Everyday Health</div>
        <p>Everyday Health independently vets all recommended products. If you purchase a featured product, we may be compensated. Learn why you can trust us. Everyday Health independently vets all ...</p>
        <div class="news-date">2024-11-18</div>
    </div>
    
    <div class="news-card">
        <span class="company-tag">Fort Health</span>
        
        <h3 class="news-title"><a href="https://medcitynews.com/tag/fort-health/" target="_blank">Fort Health</a></h3>
        <div class="news-source">MedCity News</div>
        <p>Fort Health, a new startup built at Redesign Health, recently launched as a provider of mental healthcare services for children. The company has developed a telehealth-based mental health clinic ...</p>
        <div class="news-date">2023-02-09</div>
    </div>
    
    <div class="news-card">
        <span class="company-tag">RubyWell</span>
        
        <h3 class="news-title">No news</h3>
        <div class="news-source"></div>
        <p></p>
        
    </div>
    
    <div class="news-card">
        <span class="company-tag">Atlantic Sea Farms</span>
        
        <h3 class="news-title"><a href="https://civileats.com/2022/03/16/can-small-seaweed-farms-help-kelp-scale-up/" target="_blank">Can Small Seaweed Farms Help Kelp Scale Up?</a></h3>
        <div class="news-source">Civil Eats</div>
        <p>Atlantic Sea Farms, the first commercial edible seaweed farm in the U.S.â€”founded in 2006 under the name Ocean Approvedâ€”is poised to take advantage of the moment. When Briana Warner, 37, took over as CEO in mid-2018, the Maine-based company was ...</p>
        <div class="news-date">2022-03-16</div>
    </div>
    
    <div class="news-card">
        <span class="company-tag">Atlantic Sea Farms</span>
        
        <h3 class="news-title"><a href="https://www.mainebiz.biz/article/with-new-retail-products-atlantic-sea-farms-seeks-to-expand-kelp-market" target="_blank">With new retail products, Atlantic Sea Farms seeks to expand kelp market</a></h3>
        <div class="news-source">Mainebiz</div>
        <p>Atlantic Sea Farms A kelp farm can produce three to seven pounds per foot of line. With up to 18,000 feet of line in the water, &quot;that&#x27;s a lot of kelp,&quot; said Atlantic Sea Farms CEO Briana Warner.</p>
        <div class="news-date">2019-04-17</div>
    </div>
    
    <div class="news-card">
        <span class="company-tag">VidaFuel</span>
        
        <h3 class="news-title"><a href="https://www.bizjournals.com/nashville/news/2018/05/29/jumpstart-foundry-announces-2018-portfolio-brings.html" target="_blank">Jumpstart Foundry announces 2018 portfolio, brings startups to Nashville</a></h3>
        <div class="news-source">The Business Journals</div>
        <p>Jumpstart Foundry brought 13 health care startups to Music City for two days of health care industry networking. Jumpstart Foundry announced its 2018 investment portfolio Tuesday, but the process ...</p>
        <div class="news-date">2018-05-29</div>
    </div>
    
    <div class="news-card">
        <span class="company-tag">VidaFuel</span>
        
        <h3 class="news-title"><a href="https://www.digitaljournal.com/pr/4861343" target="_blank">Vidafuel Nutrition Closes Oversubscribed $1.075 Million Financing to Advance its Clinical Nutrition Brand</a></h3>
        <div class="news-source">Digital Journal</div>
        <p>Vidafuel, a company developing next-generation clinical nutrition products for use at-home and in the healthcare setting, announced it has closed an oversubscribed $1.075 million financing.</p>
        <div class="news-date">2020-10-30</div>
    </div>
    
    <div class="news-card">
        <span class="company-tag">Aloqia</span>
        
        <h3 class="news-title"><a href="https://www.msn.com/en-xl/news/other/shein-increases-use-of-deadstock-fabric-by-40-in-2024/ar-AA1CbCXN" target="_blank">Shein increases use of deadstock fabric by 40% in 2024</a></h3>
        <div class="news-source">MSN</div>
        <p>Since 2022, Shein has sourced over 47,900 metres of deadstock fabric through Aloqia, leading to estimated savings of 357,600 cubic metres of water, 7,400 kilograms of chemicals, and 70 metric tons ...</p>
        <div class="news-date">2025-04-03</div>
    </div>
    
    <div class="news-card">
        <span class="company-tag">Refiberd</span>
        <div class="news-image"><img src="https://img-s-msn-com.akamaized.net/tenant/amp/entityid/AA1Go37I.img?w=1440&amp;h=810&amp;m=4&amp;q=81" alt="Refiberd scores $200k PDS Ventures investment on GFA Trailblazer win"></div>
        <h3 class="news-title"><a href="https://www.msn.com/en-us/money/technologyinvesting/refiberd-scores-200k-pds-ventures-investment-on-gfa-trailblazer-win/ar-AA1Go12T" target="_blank">Refiberd scores $200k PDS Ventures investment on GFA Trailblazer win</a></h3>
        <div class="news-source">Just Style</div>
        <p>Refiberd has been named the recipient of the Global Fashion Agenda Trailblazer Programme 2025 award, securing an investment of up to $200,000 from PDS Ventures.</p>
        <div class="news-date">2025-06-09</div>
    </div>
    
    <div class="news-card">
        <span class="company-tag">Refiberd</span>
        
        <h3 class="news-title"><a href="https://www.msn.com/en-us/lifestyle/lifestyle-buzz/refiberd-wins-trailblazer-2025-with-ai-powered-textile-recycling/ar-AA1GeqUb" target="_blank">Refiberd Wins Trailblazer 2025 With AI-Powered Textile Recycling</a></h3>
        <div class="news-source">Sourcing Journal</div>
        <p>AI-powered textile recycling startup Refiberd won the Global Fashion Agenda&#x27;s second Trailblazer Programme award.</p>
        <div class="news-date">2025-06-06</div>
    </div>
    
    <div class="news-card">
        <span class="company-tag">Jiminy&#x27;s</span>
        
        <h3 class="news-title"><a href="https://grist.org/food/sustainable-cricket-dog-food-jiminys/" target="_blank">Pets eat a lot of meat. Insects could lower their carbon pawprint.</a></h3>
        <div class="news-source">Grist</div>
        <p>Here&#x27;s How Anne Carlson, the founder and CEO of Jiminy&#x27;s, discovered this when she began experimenting with bringing insect protein to the pet food industry. She started with cricket treats ...</p>
        <div class="news-date">2022-09-13</div>
    </div>
    
    <div class="news-card">
        <span class="company-tag">Jiminy&#x27;s</span>
        
        <h3 class="news-title"><a href="https://nymag.com/strategist/article/jiminys-cricket-treats-review.html" target="_blank">My Dog Loves These Cricket Protein Treats More Than She Loves Me</a></h3>
        <div class="news-source">New York Magazine</div>
        <p>That seems more like something you do for a pet snake than a toy poodle. But when a bag of Jiminy&#x27;s cricket treats were sent to the office by a publicist, I decided to bring them home.</p>
        <div class="news-date">2020-02-19</div>
    </div>
    
    <div class="news-card">
        <span class="company-tag">Aeromutable</span>
        
        <h3 class="news-title">No news</h3>
        <div class="news-source"></div>
        <p></p>
        
    </div>
    
    </div>
    <p class="timestamp">Last updated: 2025-06-11<br>Please reload this web page by pressing shortcut keys â€” Command (âŒ˜)-R on Mac or Ctrl+R on Windows â€” if date appears older than a week.</p>
    
    <!-- Chatbot UI - Added title attribute and more visible text -->
    <button class="chat-toggle-button" title="Open Chat Assistant">ðŸ’¬</button>
    <div class="chatbot-container">
        <div class="chatbot-header">
            <span class="chatbot-title">News Assistant</span>
            <span class="close-chat" style="cursor: pointer;">âœ•</span>
        </div>
        <div class="chatbot-messages">
            <div class="message bot-message">
                Hi! I'm your news assistant. Ask me anything about the news articles on this page.
            </div>
        </div>
        <div class="chatbot-input">
            <input type="text" placeholder="Ask a question...">
            <button>Send</button>
        </div>
    </div>
    
    <script>
        const newsData = [{"company": "Unaliwear", "title": "UnaliWear Medical Alert Watch Review In 2025", "url": "https://www.forbes.com/health/medical-alert-systems/unaliwear-review/", "source": "Forbes", "body": "Our editors also may be in touch with follow-up questions. The water-resistant UnaliWear Kanega Watch is a medical alert device that provides automatic fall detection, 24/7 monitoring and ...", "date": "2024-02-15", "full_content": "The Forbes Health editorial team is independent and objective. To help support our reporting work, and to continue our ability to provide this content for free to our readers, we receive compensation from the companies that advertise on the Forbes Health site. This compensation comes from two main sources.First, we provide paid placements to advertisers to present their offers. The compensation we receive for those placements affects how and where advertisers\u2019 offers appear on the site. This site does not include all companies or products available within the market.Second, we also include links to advertisers\u2019 offers in some of our articles; these \u201caffiliate links\u201d may generate income for our site when you click on them.\n\nThe compensation we receive from advertisers does not influence the recommendations or advice our editorial team provides in our articles or otherwise impact any of the editorial content on Forbes Health. While we work hard to provide accurate and up-to-date information that we think you will find relevant, Forbes Health does not and cannot guarantee that any information provided is complete and makes no representations or warranties in connection thereto, nor to the accuracy or applicability thereof.\n\nHave a question for Eliene Augenbraun or our other editors?\n\nAsk here for a chance to be featured in a story.\n\nSend a note to\n                                                    Eliene Augenbraun,\n                                                    Carley Prendergast\n                                            and our other editors. We read every email.\n\nKeep reading Forbes Advisor for the chance to see the answer to your question in one of our upcoming stories. Our editors also may be in touch with follow-up questions.\n\nThe water-resistant UnaliWear Kanega Watch is a medical alert device that providesautomatic fall detection, 24/7 monitoring and emergency response assistance via voice activation, the press of a button or its easy-to-read screen. It also looks more like a digital watch than a medical alert device.FEATURED PARTNER OFFERWe receive compensation from our partners for Featured Partner Offer placements. While this may influence where their products or services appear on our site, it in no way affects our ratings, which are based on thorough research, solid methodologies and expert advice. Our partners cannot pay us to guarantee favorable review of their products or services.75% Off MGMiniUsing Code MEGASAVINGSMedical Guardian MGClassicStay active in and around your home with 1,300 feet of coverageConnects to your landline telephone32 hours of backup battery power for protection during power outagesTranslation services for emergency response available in 70 languagesAutomatic fall detection available for additional $10 per monthCall NowLearn MoreOn Medical Guardian's Website\n\nUnaliWear, Inc. is the manufacturer of the Kanega Watch, amedical alert watchthat offers 24/7 monitoring via a discreet wearable. \u201cUnalii\u201d is the Cherokee word for \u201cfriend\u201d and \u201cKanega\u201d means \u201cspeak,\u201d so the product\u2019s name translates to \u201cfriend that speaks to you,\u201d according to the company\u2019s website.\n\nThe Texas-based company was founded in April 2013 by CEO Jean Anne Booth, a serial entrepreneur and electrical engineer with 30 years of technology development experience. She retired after selling two other companies she founded, but she was inspired to rejoin the workforce to address problems faced by her mother, who was active but frail and wanted to age in place safely.\n\n\u201c[S]ome of the best stuff I think gets created because of the need, and needs are just not being met in silver tech,\u201d says Booth, noting that none of themedical alert systemsavailable in 2013 would have worked for her mother (theApple Watchdidn\u2019t hit store shelves until April 2015). \u201cThependantis super stigmatizing. And the problem is even with a pendant, you take it off at night because of the threat of choking. Yet the number one cause of injury among older adults is falls\u2014mostly in the bathroom and mostly at night,\u201d explains Booth. \u201cWe realized we could build a watch that you could wear 24/7.\u201d\n\nThe UnaliWear Kanega Watch is disguised discreetly as a digital wristwatch to avoid the potential stigma of wearing a medical alert device. It can interact with the wearer via voice, a push button and large white-on-black text on its screen. The watch is water-resistant, so users can wear it in the shower, although it\u2019s not recommended for swimming. The watch comes with four rechargeable lithium-ion batteries, which can be swapped in and out without taking off the watch.\n\nWhen users first receive the watch, they provide UnaliWear with any relevant medical information.\n\nThe watch connects to the internet and an emergency response operator via Wi-Fi and runs exclusively on the Verizon 4G/5G cellular network nationwide. If an emergency occurs, (the user falls or calls for help), the watch\u2019sGPScan help locate them. It also connects them to an emergency response operator in seconds.\n\nUnaliWear\u2019s emergency response center is a U.S.-based, third-party provider that\u2019s Five Diamond certified by TMA, the monitoring industry\u2019s highest standard. The operators have each customer\u2019s provided medical information on hand to help determine what kind of help should be sent when they receive a call.\n\nTo start talking to the Kanega Watch, say, \u201cFred Astaire,\u201d and give it a command.\n\nSince no two people share identical falling patterns, the watch uses artificial intelligence (AI) to learn about each user\u2019s movements. If the watch detects what might be a fall and the wearer tells the alert center that they didn\u2019t fall, the AI learns to ignore similar movements of that user in the future.\n\nThe watch face includes a black screen with white text and comes in three accent colors: rose gold, champagne gold and black. Each watch strap is black no matter the accent color selected.\n\nUnaliWear offers two monitoring subscription options for the Kanega Watch: the annual plan and the monthly plan.\n\nFor the annual plan, users pay for device setup and 12 months of service upfront. Costs include a $199 one-time setup fee and$59.95 per month for ongoing monitoring and service. The total upfront cost is $918.40.\n\nFor the monthly plan, users pay for device setup and the first month of service upfront. Costs include a $299 one-time setup fee and$69.95 for one month of monitoring service, totaling $368.95 upfront.", "extraction_status": "cached"}, {"company": "Unaliwear", "title": "UnaliWear Kanega Watch Reviews", "url": "https://www.consumeraffairs.com/medical-alert-systems/unaliwear-kanega-watch.html", "source": "ConsumerAffairs", "body": "The UnaliWear Kanega Watch is a more discreet alternative to traditional medical alert devices. The watch weighs 49 grams (about 1.7 ounces). It's 1.6 inches in diameter and 0.5 inches thick.", "date": "2025-05-13", "full_content": "Our Buyers Guide Top Picks\n\nThe UnaliWear Kanega Watch is a more discreet alternative to traditional medical alert devices. The watch weighs 49 grams (about 1.7 ounces). It\u2019s 1.6 inches in diameter and 0.5 inches thick. It comes with a patented quick-swap battery, so you never have to take it off to charge.\n\nThe UnaliWear Kanega Watch is a stand-alone personal emergency response device, so you don\u2019t need a landline or cellphone to make it work. Instead, it relies on Verizon\u2019s nationwide cellular network. The watch connects to your home Wi-Fi but automatically switches to Verizon\u2019s network when you leave your home.\n\nYou can call for help in multiple ways. If you press and hold the button on the right side of the watch (called the crown button) for a couple of seconds, you\u2019ll be connected to the monitoring center. These trained professionals have your contact information and the names of your caregivers and know exactly whom to notify and where to dispatch help.\n\nYou can also use voice commands through the watch\u2019s built-in microphone. Finally, if you fall, the watch automatically detects the unusual movement and notifies the monitors.\n\nUnaliWear offers two different pricing structures for the Kanega Watch. You can make an upfront payment for the whole year, or you can pay monthly from the start. No matter how you pay, you have a one-time setup fee.\n\nAs of publishing, if you choose to pay monthly from the start, your one-time setup fee is $299. Then, you\u2019ll pay $69.95 a month for monitoring services.\n\nThere\u2019s no contract with either payment structure, so you can cancel the service anytime. But note that the watch and the accessories aren\u2019t yours to keep. You have to return everything in good condition if you cancel the monitoring service.\n\nDesigned with an older user in mind, the UnaliWear Kanega Watch has many features to help improve independence, including:\n\nCompare UnaliWear with othermedical alert companies.\n\nThe company name comes from the Cherokee words \u201cUnalii,\u201d which means friend, and \u201cKanega,\u201d which means speak. When you put them together, you have a friend who speaks to you.\n\nUnaliWear covers defects in materials and workmanship for as long as you have it, as long as you are current on your service payments. If any issues come up, UnaliWear will replace the watch for free.\n\nThe company also covers replacement and shipping at no cost the first time you break the watch. Be aware that UnaliWear does not cover replacement of a watch in all circumstances.\n\nAfter 30 days, you can cancel the service at any time as long as you return all equipment. You\u2019ll get a refund (minus a $75 restocking fee) if all equipment is returned in good condition. Annual plans will be issued a prorated refund based on the nondiscounted monthly rate of $69.95.\n\nTo cancel your monitoring service through UnaliWear, you need to call the company\u2019s customer support team. As a part of the cancellation, you must send the equipment back in good condition. A lost or damaged watch results in a fee of up to $650.\n\nThe company\u2019s headquarters is in Austin, Texas.\n\nUnaliWear helps vulnerable people enjoy more independence through its medical alert technology. The stylish Kanega Watch includes 24/7 U.S.-based monitoring, fall detection, medication reminders and a 30-day money-back guarantee. Since the watch uses Wi-Fi and LTE technologies, wearers don\u2019t need a landline to access help. In addition, UnaliWear doesn\u2019t require a long-term contract.\n\nShop with confidence\n\nCompare with top companies\n\nFilter by Rating\n\nPopular Mentions\n\nA link has directed you to this review. Its location on this page may change next time you visit.\n\nReviewed Sept. 17, 2024\n\nThe Kanega Watch has been a lifesaver for my grandma (and mom!). My grandma lives independently and is able to continue to do so because the Kanega provides round the clock coverage in the case of an emergency. And even better, my mom can rest easy, knowing she's safe. We chose the Kanega because the 24/7 monitoring service already knows who she is when an alert comes from the watch. After doing so much research online, we found that the Kanega's coverage and service was far superior to others on the market. Totally worth the price!\n\nReviewed March 12, 2024\n\nI bought this watch for my mother in December 2023. Two months later the screen went blank and it was not usable. I made several calls and wrote emails to the company's customer service department. The calls repeatedly were answered by the \"overflow\" service department, which was not qualified to actually troubleshoot problems. After a week of no response on how to fix the watch, I returned it. If you want a watch that detects falls and will notify emergency services, I would suggest an Apple Watch. The Apple Watch does everything the Kanega does and more, and it costs less.\n\nThanks for subscribing.\n\nYou have successfully subscribed to our newsletter! Enjoy reading our tips and recommendations.\n\nReviewed Feb. 17, 2024\n\nThe watch band was too large even though the wrist measured within the range for small. And the watch was heavy, too heavy for a small person to sleep when wearing. This may work better for larger folks, but if you're small, I would not recommend it. The $75 return fee is very steep and you need to go through customer service, which tries and tries to change your mind, to return it.\n\nReviewed Nov. 15, 2023\n\nWe got the Kanega Watch for my father several years ago. He loves it and he wears it all the time, which is the total point. The fall detection has worked as advertised, and he enjoys asking his watch for the time and date. Tremendous peace of mind for him and our whole family. I highly recommend!\n\nReviewed Oct. 22, 2023\n\nI purchased the watch on 9/6/2023, I received it around 9/11/2023. I lost a battery out of it on 10/2/2023, I had no idea how I lost it. Now on 10/22/2023 the watch band has broken where it attaches with the battery to watch. Very unhappy with the construction as I bought a battery for about $36 plus shipping about 3 weeks after purchase and now about 6 weeks later it is broken. I am emailing the company today to see what they will do about this situation. I paid $918.40. I would expect a better quality.\n\nReviewed Sept. 16, 2023\n\nThe service is great. There is very little set up and it is very easy to do. Once we received the watch there were 3 very short videos to watch and then you call the center and they do a test call with you. My Aunt loves the device because it isn't a pendant that gets in the way, flops around or looks out of place when she dresses up and goes out. She also likes the fact that she never has to take it off and can wear it in the shower.\n\nOur only complaint is that after only 3 months the first watch band broke where the battery goes in. We didn't realize it cracked and one battery was lost and then the band broke all together. I believe that a more rubberized battery chamber would be a better housing for the battery. The other disappointment was we had to pay $50 for shipping for a new watch. This seems a bit steep. We haven't found anything better at this time but the shipping cost did cause the luster of this product to dull somewhat.\n\nCheck out our buyers guide top picks\n\nOur Buyers Guide Top Picks:", "extraction_status": "cached"}, {"company": "BrainCheck", "title": "BrainCheck Expands First End-to-End Solution for Cognitive Care", "url": "https://finance.yahoo.com/news/braincheck-expands-first-end-end-130000828.html", "source": "Yahoo Finance", "body": "Company introduces next generation of its comprehensive platform and 3-minute screening tool at Clinical Trials on Alzheimer's Disease (CTAD) conference New research supporting BrainCheck platform ...", "date": "2023-10-24", "full_content": "Content extraction failed: 404 Client Error: Not Found for url: https://finance.yahoo.com/news/braincheck-expands-first-end-end-130000828.html", "extraction_status": "success"}, {"company": "BrainCheck", "title": "BrainCheck Secures $15 Million to Fuel Expansion and Adoption of its Next Generation Digital Cognitive Assessment and Care Planning Platform", "url": "https://www.wkrn.com/business/press-releases/cision/20240306DA53947/braincheck-secures-15-million-to-fuel-expansion-and-adoption-of-its-next-generation-digital-cognitive-assessment-and-care-planning-platform/", "source": "WKRN-TV", "body": "New financing round, led by Next Coast Ventures, S3 Ventures, and UPMC Enterprises, positions Company for continued growth, innovation, and integration BrainCheck expands Board of Directors ...", "date": "2024-03-06", "full_content": "Note: Content could not be properly extracted from this source. Using summary instead.\n\nNew financing round, led by Next Coast Ventures, S3 Ventures, and UPMC Enterprises, positions Company for continued growth, innovation, and integration BrainCheck expands Board of Directors ...", "extraction_status": "content_too_short"}, {"company": "Dermala", "title": "DERMALA, A Consumer Dermatology Company, Announces Issuance of the Second U.S. Patent Covering the Use of Novel Human Microbiome Technology for Treating Acne Vulgaris", "url": "https://markets.businessinsider.com/news/stocks/dermala-a-consumer-dermatology-company-announces-issuance-of-the-second-u-s-patent-covering-the-use-of-novel-human-microbiome-technology-for-treating-acne-vulgaris-1030899083", "source": "Business Insider", "body": "SAN DIEGO, Oct. 26, 2021 /PRNewswire/ -- DERMALA, a consumer dermatology company developing novel, personalized, microbiome-powered solutions for chronic skin conditions, announced today the ...", "date": "2021-10-26", "full_content": "SAN DIEGO,Oct. 26, 2021/PRNewswire/ --\u00a0DERMALA,\u00a0a consumer dermatology company developing novel, personalized, microbiome-powered solutions for chronic skin conditions, announced today the issuance of the U.S. Patent No. 11,154,522 -COMPOSITIONS AND METHODS FOR TREATING ACNE VULGARIS. This is the second patent in DERMALA's intellectual property portfolio that covers using the human microbiome to treat and prevent acne.\n\nAcneisthe most common skin condition that affectsover\u00a080% of adolescents. It often persists into adulthood with a negative impact on the quality of life. Acne vulgaris is characterized by microbiome dysbiosis associated with an overgrowth ofC. acnesbacteria, followed by inflammation of skin follicles. To date, many strategies have been used to treat acne. However, they often show limited efficacy accompanied by side effects, in part due to suboptimal delivery into the skin and lack of targeting.\n\nDERMALA developed a novel technology for enhanced targeted delivery of human microbiome-derived postbiotic metabolites into specific layers of the skin. This results in higher treatment efficacy due to targeted inhibition ofC. acnesin follicles and reducing inflammation while avoiding side effects.\u00a0The microbiome-derived postbiotics derived from beneficial bacteria help correct the microbiome dysbiosis associated with acne and produce faster and longer-lasting results.\n\n\"Targeted delivery is critical\u00a0for\u00a0overcoming side effects and achieving high treatment efficacy,\" said Dr. Lada Rasochova, founder and CEO of DERMALA. \"Granting of this patent recognizes the uniqueness of our delivery approach and further enhances the value of our microbiome technology as it allows for formulating microbiome-derived ingredients into specific, efficacious, and effective topical products\".\n\nThis patent is an important part of the fast-expanding DERMALA's intellectual property portfolio which focuses on using the human microbiome for improving skin health and treating skin conditions like acne and eczema.\n\nAbout DERMALADERMALA, Inc. is aSan Diego-based consumer dermatology company leveraging a scientific understanding of the human microbiome and data analytics to develop novel treatments for chronic skin conditions. The company's #FOBO\u00ae(Fear of Breaking Out) Kit, a personalized, microbiome-powered solution for acne, combines patented topical treatments and oral supplements with the DERMALA Acne Tracker app that customers use to track their skin health and get their product formulations optimized. For more information, visitwww.dermala.com.\n\nPress Contact:Erica@LazarusPR.com\n\nView original content to download multimedia:https://www.prnewswire.com/news-releases/dermala-a-consumer-dermatology-company-announces-issuance-of-the-second-us-patent-covering-the-use-of-novel-human-microbiome-technology-for-treating-acne-vulgaris-301408177.html\n\nSOURCE  DERMALA", "extraction_status": "cached"}, {"company": "Dermala", "title": "DERMALA Announces $6.73 Million Series A Financing to Expand and Scale Company's Personalized Microbiome-Based Solutions for Acne and Other Skin Conditions", "url": "https://www.businesswire.com/news/home/20201109005312/en/DERMALA-Announces-6.73-Million-Series-A-Financing-to-Expand-and-Scale-Company\u2019s-Personalized-Microbiome-Based-Solutions-for-Acne-and-Other-Skin-Conditions", "source": "Business Wire", "body": "SAN DIEGO--(BUSINESS WIRE)--DERMALA, Inc., a consumer dermatology company developing novel, personalized, microbiome-based solutions for acne and other skin conditions, announced today that it has ...", "date": "2020-11-09", "full_content": "DERMALA Announces $6.73 Million Series A Financing to Expand and Scale Company\u2019s Personalized Microbiome-Based Solutions for Acne and Other Skin Conditions\n\nJohnson & Johnson Innovation \u2013 JJDC, Inc. and True Wealth Ventures co-led the funding round, joined by Seventure Partners and Cove Fund\n\nSAN DIEGO--(BUSINESS WIRE)--DERMALA, Inc.,a consumer dermatology company developing novel, personalized, microbiome-based solutions for acne and other skin conditions, announced today that it has closed a $6.73 million Series A financing. The company developed an integrated platform that combines patent-pending microbiome-based topical and oral products containing unique prebiotic, probiotic, and postbiotic ingredients, including the SE Microbiome Complex\u00ae, with a proprietary data analytics app that enables personalization and continuous optimization of product formulations based on individual outcomes.\n\n\u201cThe consumer dermatology category is ripe for science-based solutions to treat common skin conditions,\u201d said Lada Rasochova, Ph.D., MBA, Founder and CEO of DERMALA. \u201cOne size just does not fit all when it comes to acne. Most acne treatments have been on the market for decades, but they do not work for everyone. Our proprietary platform combines human microbiome science with data analytics to identify product formulations that deliver the best results and help our customers feel confident, healthy and beautiful in their skin.\u201d\n\nDERMALA launched its #FOBO\u00ae(Fear of Breaking Out) Kit, a microbiome-based solution for acne in 2019. It has attracted many loyal customers who value its personalized approach to helping them conquer their \u201cfear of breaking out\u201d. The solution comprises topical acne treatments and oral supplements paired with the DERMALA Acne Tracker app, which customers use to track their skin health.\n\nThe Series A financing was co-led by Johnson & Johnson Innovation \u2013 JJDC, Inc. and True Wealth Ventures. Seventure Partners, investing via their Health for Life Capital\u2122 Funds, and Cove Fund joined the financing round.\n\n\u201cDERMALA brings together science-based products with robust data analytics to deliver value to the customer with a unique skin health solution,\u201d said Sara T. Brand, Founding General Partner of True Wealth Ventures. \u201cThe app enables DERMALA\u2019s product customization and helps customers with treatment compliance. It is truly unique within the OTC consumer dermatology category.\u201d\n\n\u201cExploring the richness of microbiome biology including prebiotics, probiotics and postbiotics, and combining topical and oral products for OTC dermatology makes great scientific sense,\u201d said Isabelle de Cr\u00e9moux, CEO and Managing Partner of Seventure Partners. \u201cThis, combined with creative marketing and a personalized digital program, positions DERMALA for success after this Series A investment and will allow them to scale up their operations and reach more people in need.\u201d\n\nDERMALA will use the proceeds of the funding round to scale operations, manufacturing, and commercial efforts for its acne products. It will also expand its research and development activities exploring new personalized microbiome-based products for other skin conditions including eczema and skin wellness.\n\nAbout DERMALA\n\nDERMALA, Inc. is a privately-held consumer dermatology company leveraging scientific understanding of the human microbiome to develop novel solutions for acne and other skin conditions. The company\u2019s #FOBO\u00ae(Fear of Breaking Out) Kit, a personalized microbiome-based solution for acne, combines patent-pending topical acne treatments with oral supplements and a proprietary DERMALA Acne Tracker app that customers use to track their skin health. For more information, visitdermala.com.\n\nFor Media InquiriesGwen Gordon for DERMALA, Inc.858-245-5684GwenGordonPR@outlook.com\n\nFor General InquiriesDERMALA, Inc.www.dermala.cominfo@dermala.com\n\nFor Media InquiriesGwen Gordon for DERMALA, Inc.858-245-5684GwenGordonPR@outlook.com\n\nFor General InquiriesDERMALA, Inc.www.dermala.cominfo@dermala.com\n\nFor Media InquiriesGwen Gordon for DERMALA, Inc.858-245-5684GwenGordonPR@outlook.com\n\nFor General InquiriesDERMALA, Inc.www.dermala.cominfo@dermala.com", "extraction_status": "success"}, {"company": "Oralucent", "title": "No news", "url": "", "source": "", "body": "", "date": "2025-06-11", "full_content": "", "extraction_status": "not_attempted"}, {"company": "Flowly", "title": "Flowly, VR-enabled app to manage chronic pain and stress, rolls out program for providers", "url": "https://www.fiercehealthcare.com/digital-health/relaxation-app-vr-startup-flowly-rolls-out-program-providers", "source": "Fierce Healthcare", "body": "Flowly, an app for autonomic nervous system regulation, has launched a program for providers, the company has shared exclusively with Fierce Healthcare. Through the program, providers will receive ...", "date": "2023-03-13", "full_content": "Flowly, an app for autonomic nervous system regulation, has launched a program for providers, the company has shared exclusively with Fierce Healthcare.\n\nThrough the program, providers will receive a virtual reality headset, a heart rate sensor, an onboarding session and access to a portal tracking patient progress.\n\nFounded in 2020, Flowly relies on the stimulating and immersive nature of VR to draw a user\u2019s attention away from pain. By being able to visualize one\u2019s heart rate and breathing, users can learn to regulate their nervous system. The company has gone through several clinical trials, received a grant from the National Institutes of Health and also participated in Y Combinator.\n\nDuring COVID-19, Flowly saw an influx in providers interested in its product\u2014for use on themselves, co-founder and CEO Celine Tien told Fierce Healthcare. They were also eager to receive information about innovative ways to use pain management and anxiety therapies. \u201cThe problem with our healthcare model today is that so many providers live in their own silos,\u201d Tien said.\n\nTo help bridge gaps in knowledge, Flowly created a founding board of physicians, with 15 active members, where they share creative ways of using Flowly in practice. Members of the board also get access to the latest research, data and features from Flowly and can offer feedback to improve the product. Some members also work with Flowly to design lectures on their domain expertise. Nearly all members of the board have used Flowly themselves, Tien said.\n\nJaimee Arnoff, Ph.D., a licensed clinical psychologist specializing in young adults, initially heard about Flowly on a podcast. As someone with chronic pain, Arnoff reached out to try the product. \u201cAs a provider, I always love to try any app,\u201d Arnoff told Fierce Healthcare, especially one she might suggest to her clients.\n\nAfter using Flowly for a few months, she was convinced it was worth recommending to her patients as an option. \u201cIt was great to kind of focus on something so all-consuming,\u201d Arnoff said. \u201cIt\u2019s beautiful; it\u2019s relaxing.\u201d\n\nPatients can use Flowly before, during or after a treatment session to help calm their nervous system. \u201cThere are many days with clients where we are asking them to lean into this very uncomfortable place,\u201d Arnoff said. \u201cFlowly is a great way to kind of debrief and kind of come down from a heightened state of emotional or physical state that we might find ourselves in together.\u201d\n\nSome of Arnoff\u2019s patients buy Flowly for their personal use outside of treatment sessions.\n\nFlowly currently has more than 10,000 users and is so far used by more than 100 providers.", "extraction_status": "cached"}, {"company": "Flowly", "title": "Flowly Offers Relief to 100 Million Americans Living with Chronic Pain and Anxiety", "url": "https://www.businesswire.com/news/home/20200609005289/en/Flowly-Offers-Relief-to-100-Million-Americans-Living-with-Chronic-Pain-and-Anxiety", "source": "Business Wire", "body": "LOS ANGELES--(BUSINESS WIRE)--Flowly today officially launched its interactive mobile app to address chronic pain and anxiety. The platform offers immersive experiences in beautiful and peaceful ...", "date": "2020-06-09", "full_content": "Flowly Offers Relief to 100 Million Americans Living with Chronic Pain and Anxiety\n\nMobile app manages symptoms through virtual reality and relaxation training anytime, anywhere\n\nFlowly Mobile app manages symptoms through virtual reality and relaxation training anytime, anywhere (Photo: Business Wire)\n\nLOS ANGELES--(BUSINESS WIRE)--Flowlytoday officially launched its interactive mobile app to address chronic pain and anxiety. The platform offers immersive experiences in beautiful and peaceful virtual reality and 360\u00b0 worlds that engage users in biofeedback for relaxation training. Flowly allows users to access the virtual worlds anytime, anywhere on their phones or with VR headsets to monitor and adjust how they breathe, focus, and learn how to better regulate their own nervous systems. For a look into Flowly\u2019s virtual worlds and to see the app in action, watchthis video.\n\nFlowly has also created a special session that specifically targets Coronavirus-related anxiety, and makes a monetary donation towards COVID-19 relief efforts upon completion. Additionally, in light of recent tragic events that have amplified the Black Lives Matter movement, Flowly is standing with the Black community and offering afree month\u2019s subscription to POCwho have anxiety, sleep deprivation and/or other symptoms as a result of race-based triggers. Flowly is available for download in theApp Storeand atwww.flowly.world.\n\n\u201c100 million Americans of all ages suffer from chronic pain and anxiety,\u201d said Celine Tien, co-founder & CEO, Flowly. \u201cFlowly is the first interactive platform to make pain management accessible, and address all parts of pain: physical, psychological, and even social. Flowly is engaging, gamified and community-based.\u201d\n\nKey features of the Flowly app include:\n\nFlowly is founded by Celine Tien, a storyteller from Yale, who aimed to create a platform that not only addressed physical pain, but also the anxiety, depression and social isolation that accompanies it. She called upon cofounder and Yale engineer, Julien Soros, to create an accessible biofeedback system and then rounded out the trio with award-winning designer and 3D artist, cofounder Narae Kim, to create the app\u2019s virtual worlds. The team is supported by an advisory board made up of a world-class group of doctors and therapists.\n\n\u201cFlowly has developed a pain and anxiety management platform that is not only intelligent, but thoughtful as well,\u201d said Aman Mahajan, MD, PhD, and Chair of Perioperative Medicine at University of Pittsburgh Medical Center. \u201cFlowly\u2019s comprehensive approach helps manage not only the physical aspects of living with pain and anxiety, but also offers invaluable support to overcome the mental challenges that come along with it.\u201d\n\nFlowly offers the first eight Flowly Intro sessions and #BreatheTogether experience to all users whodownload the app. Users can then access the full Flowly platform with either a Basic or Pro subscription (more information available in the app).\n\nTo learn more about Flowly and to start managing your pain and anxiety today, visitwww.flowly.world.\n\nAbout Flowly\n\nFlowly is your app for chronic pain, stress and anxiety. Founded in 2019 by two Yale classmates and an award-winning designer, Flowly\u2019s mission is to take typically inaccessible therapies like biofeedback and virtual reality, and put it in the hands of the people who need it most. The company\u2019s easy-to-use and accessible interactive platform guides users in relaxation training to regulate their nervous systems while immersed in beautiful and relaxing virtual environments. Flowly tracks user progress and offers an online community forum to share and support with other members. To learn more, visitwww.flowly.world.\n\nFlowlyDonna Loughlin Michaels(408) 393-5575donna@lmgpr.com\n\nFlowlyDonna Loughlin Michaels(408) 393-5575donna@lmgpr.com\n\nFlowlyDonna Loughlin Michaels(408) 393-5575donna@lmgpr.com", "extraction_status": "cached"}, {"company": "Rosy Wellness", "title": "Dar\u00e9 Bioscience and Rosy Wellness Announce Strategic Collaboration to Educate and Market Dar\u00e9's DARE to PLAY Sildenafil Cream", "url": "https://finance.yahoo.com/news/dar-bioscience-rosy-wellness-announce-120000637.html", "source": "Yahoo Finance", "body": "Collaboration will leverage Rosy Wellness' extensive reach and community of over 250,000 women Rosy Wellness is a multi-award winning app recommended by 8,000+ healthcare professionals Dar\u00e9 expects to start recording revenue in the 4th quarter this year SAN DIEGO,", "date": "2025-06-04", "full_content": "Collaboration will leverage Rosy Wellness\u2019 extensive reach and community of over 250,000 women\n\nRosy Wellness is a multi-award winning app recommended by 8,000+ healthcare professionals\n\nDar\u00e9 expects to start recording revenue in the 4th quarter this year\n\nSAN DIEGO, June 04, 2025 (GLOBE NEWSWIRE) -- Dar\u00e9\u00a0Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority, and Rosy Wellness, a pioneering digital platform focused on providing lifespan support for women, today announced a strategic collaboration to support the upcoming marketing and consumer and healthcare provider awareness campaign for Dar\u00e9\u2019s DARE to PLAY Sildenafil Cream.\n\nDar\u00e9\u2019s DARE to PLAY Sildenafil Cream is a proprietary topical formulation of sildenafil citrate, the same active ingredient in Viagra\u00ae, developed specifically to increase blood flow locally to genital tissues, which is part of the sexual arousal response in women. The company is targeting availability by prescription in the United States in the 4thquarter 2025 as a compounded drug under Section 503B of the FDCA.\n\nThis partnership brings together Dar\u00e9\u2019s clinical expertise and innovation in women's health with Rosy\u2019s digital reach and content-driven community engagement model, which includes a community of 250K+ women. Concerns with arousal were reported by 65% of those women who completed the Female Sexual Function Index screener questionnaire. The collaboration will center on educational outreach, consumer and healthcare provider engagement, and companion digital support to destigmatize conversations around female sexual health and promote awareness of DARE to PLAY Sildenafil Cream, helping women regain intimacy and satisfaction in their lives.\n\n\u201cFemale sexual health remains significantly underserved, and we believe our DARE to PLAY Sildenafil Cream represents a meaningful advancement,\u201d said Sabrina Martucci Johnson, President and CEO of Dar\u00e9 Bioscience. \u201cPartnering with Rosy allows us to connect with women in a trusted, authentic space that encourages open discussion and education about sexual wellness.\u201d\n\nRosy, known for its innovative and evidence-based approach to women\u2019s sexual health through education, CBT-based (Cognitive Behavioral Therapy) exercises, expert-led health coaching, and community support, will support the launch with a comprehensive digital strategy including educational campaigns, and a companion care platform aimed at increasing understanding of female sexual health and supporting DARE to PLAY Sildenafil Cream\u2019s users throughout their journey.\n\n\u201cAt Rosy, we\u2019re committed to closing gaps in women\u2019s healthcare with evidence-based, accessible solutions,\u201d said Lyndsey Harper, MD, Founder and CEO of Rosy. \u201cThis partnership with Dar\u00e9 accelerates our efforts to bring much needed attention and resources to sexual wellness, a historically stigmatized area. Together, we can expand sexual wellness education, access, and support for women.\"\n\nThe partnership underscores a shared commitment to advancing sexual health equity and ensuring women have access to both the information and solutions they need.\n\nFor more information, please visitwww.darebioscience.comandwww.meetrosy.com.\n\nAbout Rosy Wellness\n\nRosy is a leading women's health platform dedicated to empowering women with evidence-based resources, expert support, and community connection, starting with sexual health and expanding across the full spectrum of the health of women. Founded by Lyndsey Harper, a board-certified OB-GYN, Rosy addresses long-overlooked aspects of women's care through an accessible digital platform that combines personalized education, self-guided tools, community, and health coaching.\n\nWhether tackling issues like sexual dysfunction, menopause, migraine, or emotional well-being, Rosy provides judgment-free, medically backed support designed for real life. By combining evidence-based support with user-friendly technology, Rosy is redefining how women take charge of their health and experience more fulfilling lives.\n\nAbout Dar\u00e9 Bioscience\n\nDar\u00e9 Bioscience is a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority. Dar\u00e9 believes that innovation does not have to start from scratch. The company\u2019s goal is to bring to market as soon as practicable innovative evidence-based solutions that address decades of unmet needs in women\u2019s health and enhance outcomes and convenience, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. The potential products Dar\u00e9 identifies, in many cases, already have clinical proof of concept or existing safety data for the active ingredient that the company leverages. This provides optionality and flexibility, in many cases, in how Dar\u00e9 seeks to bring solutions to market in ways designed to optimize access for women in a fiscally responsible manner.\n\nThe first FDA-approved product to emerge from Dar\u00e9\u2019s portfolio of women\u2019s health product candidates is XACIATO\u2122 (clindamycin phosphate) vaginal gel 2%, a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. Visit www.xaciato.com for information about XACIATO. Dar\u00e9\u2019s portfolio also includes potential first-in-category candidates in clinical development: Ovaprene\u00ae, a novel, hormone-free monthly intravaginal contraceptive whose U.S. commercial rights are under a license agreement with Bayer; Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil citrate, the active ingredient in an oral erectile dysfunction drug for men, to treat female sexual arousal disorder (FSAD); and DARE-HRT1, a combination bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy. To learn more about Dar\u00e9\u2019s full portfolio of women\u2019s health product candidates and mission to deliver differentiated therapies for women, please visit www.darebioscience.com.\n\nDar\u00e9 Bioscience leadership has been named on the Medicine Maker\u2019s Power List and Endpoints News\u2019 Women in Biopharma and Dar\u00e9's CEO has been honored as one of Fierce Pharma\u2019s Most Influential People in Biopharma for Dar\u00e9\u2019s contributions to innovation and advocacy in the women\u2019s health space.\n\nDar\u00e9 may announce material information about its finances, product and product candidates, clinical trials and other matters using the Investors section of its website (http://ir.darebioscience.com), SEC filings, press releases, public conference calls and webcasts. Dar\u00e9 will use these channels to distribute material information about the company and may also use social media to communicate important information about the company, its finances, product and product candidates, clinical trials and other matters. The information Dar\u00e9 posts on its investor relations website or through social media channels may be deemed to be material information. Dar\u00e9 encourages investors, the media, and others interested in the company to review the information Dar\u00e9 posts in the Investors section of its website and to follow these X (formerly Twitter) accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the list of social media channels the company may use to communicate information will be posted in the Investors section of Dar\u00e9\u2019s website.\n\nForward-Looking Statements\n\nDar\u00e9 cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as \u201cbelieve,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cestimate,\u201d \u201ccontinue,\u201d \u201canticipate,\u201d \u201cdesign,\u201d \u201cintend,\u201d \u201cexpect,\u201d \u201ccould,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201ccontemplate,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201cobjective,\u201d \u201con track,\u201d or the negative version of these words and similar expressions. In this press release, forward-looking statements include, but are not limited to, statements relating to Dar\u00e9\u2019s go-to-market strategies; Dar\u00e9\u2019s plans and timing for making its proprietary formulation of sildenafil citrate available by prescription in the U.S. as a compounded drug via Section 503B of Federal Food, Drug, and Cosmetic Act (FDCA); the market opportunity for the product and its ability to gain market acceptance; expected timing of revenue from sales; the potential benefits of Dar\u00e9\u2019s collaboration with Rosy Wellness; and Dar\u00e9\u2019s development plans for the investigational products in its portfolio and their respective potential to complete clinical development and obtain regulatory approval. As used in this press release, \u201cfirst-in-category\u201d is a forward-looking statement relating to the potential of a product candidate to represent a new category of product if it were to receive marketing approval for the indication for which it is being developed because Dar\u00e9 believes it would address a need in women\u2019s health that is not being met by existing U.S. Food and Drug Administration (FDA)-approved products. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Dar\u00e9\u2019s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to: Dar\u00e9\u2019s ability to raise additional capital when and as needed to execute its business strategy and continue as a going concern; the risk of delisting of Dar\u00e9\u2019s common stock from Nasdaq; the effects of macroeconomic conditions, geopolitical events, and major changes and disruptions in U.S. government policies and operations on Dar\u00e9\u2019s ability to raise additional capital or on Dar\u00e9\u2019s operations, financial results and condition, and ability to achieve current plans and objectives; Dar\u00e9\u2019s ability to enter into and maintain third-party collaborations to facilitate access to the solutions Dar\u00e9 intends to bring to market as compounded drugs or consumer health products and Dar\u00e9\u2019s reliance on those third parties; the performance of Section 503B-registered outsourcing facilities and other third parties on which Dar\u00e9 will rely to execute its expanded business strategy; the risk that the FDA could stop permitting Section 503B-registered outsourcing facilities to compound the drug substances in the proprietary formulations Dar\u00e9 intends to bring or brings to market; the degree of market demand and acceptance for the products Dar\u00e9 brings to market; Dar\u00e9\u2019s reliance on third parties to manufacture and conduct clinical trials and preclinical studies of its product candidates and commercialize XACIATO\u2122 (clindamycin phosphate) vaginal gel 2% and future products, if any; the risk that the current regulatory pathway known as the FDA\u2019s 505(b)(2) pathway for drug product approval in the U.S. is not available for a product candidate as Dar\u00e9 anticipates; Dar\u00e9\u2019s ability to achieve the product development and other milestones required for it to receive payments under its subaward and grant agreements; the potential for termination of the subaward and grant agreements before Dar\u00e9 receives additional payments; the limits on Dar\u00e9\u2019s ability to sell stock under its equity line arrangement at times it may desire to raise additional capital; Dar\u00e9\u2019s ability to develop, obtain FDA or foreign regulatory approval for, and commercialize its product candidates and to do so on communicated timelines; failure or delay in starting, conducting and completing clinical trials of a product candidate and the inherent uncertainty of outcomes of clinical trials; Dar\u00e9\u2019s ability to design and conduct successful clinical trials, to enroll a sufficient number of patients, to meet established clinical endpoints, to avoid undesirable side effects and other safety concerns, and to demonstrate sufficient safety and efficacy of its product candidates; Dar\u00e9\u2019s dependence on third parties to conduct clinical trials and manufacture and supply clinical trial material and commercial product; the risks that positive findings in early clinical and/or nonclinical studies of a product candidate may not be predictive of success in subsequent clinical and/or nonclinical studies of that candidate and that interim data or results from a particular clinical study do not necessarily predict the final results for that study; the risk that the FDA, other regulatory authorities, members of the scientific or medical communities or investors may not accept or agree with Dar\u00e9\u2019s interpretation of or conclusions regarding data from clinical studies of its product candidates; the risk that development of a product candidate requires more clinical or nonclinical studies than Dar\u00e9 anticipates; the loss of, or inability to attract, key personnel; the risk that developments by competitors make Dar\u00e9\u2019s product or product candidates less competitive or obsolete; difficulties establishing and sustaining relationships with development and/or commercial collaborators; failure of Dar\u00e9\u2019s product or product candidates, if approved, to gain market acceptance or obtain adequate coverage, pricing and reimbursement from third-party payors; Dar\u00e9\u2019s ability to retain its licensed rights to develop and commercialize a product or product candidate; Dar\u00e9\u2019s ability to satisfy the monetary obligations and other requirements in connection with its exclusive, in-license agreements covering the critical patents and related intellectual property related to its product and product candidates; Dar\u00e9\u2019s ability to adequately protect or enforce its, or its licensor\u2019s, intellectual property rights; the lack of patent protection for the active ingredients in certain of Dar\u00e9\u2019s product candidates which could expose its products to competition from other formulations using the same active ingredients; product liability claims; governmental investigations or actions relating to Dar\u00e9\u2019s products or product candidates or the business activities of Dar\u00e9, its commercial collaborators or other third parties on which Dar\u00e9 relies; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; cybersecurity incidents or similar events that compromise Dar\u00e9\u2019s technology systems or those of third parties on which it relies and/or significantly disrupt Dar\u00e9\u2019s business; and disputes or other developments concerning Dar\u00e9\u2019s intellectual property rights. Dar\u00e9\u2019s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Dar\u00e9\u2019s risks and uncertainties, you are encouraged to review its documents filed with the SEC including Dar\u00e9\u2019s recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Dar\u00e9 undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.\n\nContacts:\n\nDar\u00e9 Bioscience Investor Relationsinnovations@darebioscience.com\n\nSource: Dar\u00e9 Bioscience, Inc.", "extraction_status": "cached"}, {"company": "Rosy Wellness", "title": "Dar\u00e9 Bioscience partners with Rosy Wellness for new women's health cream", "url": "https://www.investing.com/news/company-news/dare-bioscience-partners-with-rosy-wellness-for-new-womens-health-cream-93CH-4080414", "source": "Investing", "body": "Rosy Wellness, with its community of over 250,000 women and recommendation by more than 8,000 healthcare professionals, will leverage its digital reach and content-driven model to support the launch.", "date": "2025-06-04", "full_content": "Note: Content could not be properly extracted from this source. Using summary instead.\n\nRosy Wellness, with its community of over 250,000 women and recommendation by more than 8,000 healthcare professionals, will leverage its digital reach and content-driven model to support the launch.", "extraction_status": "content_too_short"}, {"company": "De Oro Devices", "title": "De Oro Devices Names Cori Lathan, PhD, as New CEO", "url": "https://finance.yahoo.com/news/oro-devices-names-cori-lathan-220500791.html", "source": "Yahoo Finance", "body": "Dr. Lathan joins De Oro Devices from her previous role as CEO at AnthroTronix, where she successfully invented, developed, and commercialized medical technology for over 20 years before leading ...", "date": "2024-01-18", "full_content": "Dr. Lathan brings two decades of medical technology with her to drive the health tech startup forward\n\nSAN LUIS OBISPO, CA / ACCESSWIRE / January 18, 2024 /De Oro Devices, a leading innovator in medical technology for the aging and mobility-impaired population, is pleased to announce the appointment of Dr. Cori Lathan as its new Chief Executive Officer (CEO). In her new role, Lathan will focus on continuing the rapid growth De Oro Devices has seen by exploring new partnerships across the healthcare industry and working to advance its innovative technology.\n\nDr. Lathan joins De Oro Devices from her previous role as CEO at AnthroTronix, where she successfully invented, developed, and commercialized medical technology for over 20 years before leading the company through a successful exit. She has been recognized by the World Economic Forum as a Technology Pioneer and Young Global Leader and is the founding co-chair of their Global Futures Council on Human Augmentation and Longevity. Her expertise in brain health and age tech as well as mobility products positions her as a visionary leader capable of driving De Oro Devices to new heights.\n\n\"We are thrilled to welcome Dr. Cori Lathan as our new CEO,\" said Sidney Collin, Board Member, Co-founder, President and CTO at De Oro Devices. \"Her exceptional leadership, deep industry knowledge, and commitment to innovation align perfectly with our mission. As we continue to improve the lives of the mobility-impaired, I know Dr. Lathan is the right leader to take De Oro Devices forward.\"\n\n\"I am honored and excited to lead De Oro Devices into its next chapter of growth and innovation,\" said Dr. Cori Lathan. \"The team's dedication to changing lives through developing transformational medical technologies is inspiring, and I look forward to building on the company's successes to make a meaningful impact on technology for the aging population globally.\"\n\nDe Oro Devices is at the forefront of medical technology, known for creating the first non-invasive cueing technology that can be used with any mobility aid to improve mobility and decrease falls for people with mobility impairments. Learn more at www.getnexstride.com.\n\nAbout De Oro Devices\n\nDe Oro Devices is an award-winning tech startup that's restoring mobility, independence, and a higher quality of life to individuals with mobility challenges and/or heightened fall risk. De Oro's flagship product, NexStride, is a small, unobtrusive device that can attach to any assisted walking tool (i.e., cane, walker, or rollator), which leverages visual and auditory cueing technology to reduce fall risk and improve mobility. Learn more atwww.getnexstride.com.\n\nContact Information\n\nWilliam Thompsonpr@deorodevices.com\n\nSOURCE:De Oro Devices\n\nView the originalpress releaseon newswire.com.", "extraction_status": "cached"}, {"company": "De Oro Devices", "title": "New device helps Clovis veteran with Parkinson's walk again", "url": "https://abc30.com/parkinsons-disease-nexstride-device-de-oro-devices-clovis-veteran-able-to-walk/12728394/", "source": "ABC30 Action News", "body": "CLOVIS, Calif. (KFSN) -- The simple act of walking can be challenging for those living with Parkinson's disease, which affects movement. However, a Clovis veteran is now on the move with the help ...", "date": "2023-01-25", "full_content": "The device essentially uses the same visual and auditory signals or cues used in physical therapy.\n\nCLOVIS, Calif. (KFSN) --The simple act of walking can be challenging for those living with Parkinson's disease, which affects movement.\n\nHowever, a Clovis veteran is now on the move with the help of a newly-invented device.\n\n\"It feels like your feet are stuck in cement,\" explained Patrick Hallmark. \"A lot of people who have Parkinson's, you'd be going through a doorway or whatever, and your feet -- you just cannot move your feet.\"\n\nThe 63-year-old has a condition called \"Freezing of Gait,\" which can come with Parkinson's.\n\nIt can lead to falls and hospitalizations.\n\nFor Hallmark, it also came with a loss of independence.\n\n\"If I didn't have my wife or daughter with me, I would really have a hard time out going to stores and everything,\" he said.\n\nThat's all changed with a device as small as his palm.\n\n\"This has done wonders,\" Hallmark said, as he shows his NexStride device.\n\nThrough a Parkinson's support group, Hallmark learned about NexStride and immediately bought the device.\n\nNow he's walking, despite his condition.\n\nSidney Collin, CEO of De Oro Devices, explained why walking can be hard for people with Freezing of Gait.\n\n\"There's a disconnect between the brain and the body, and it makes it so that when the brain is sending that signal to initiate movement, it doesn't get to the motor neurons that are activating the muscles,\" she said.\n\nCollin, a biomedical engineer, created NexStride for a veteran while she was in college.\n\nThe device essentially uses the same visual and auditory signals or cues used in physical therapy.\n\n\"The visual cue that we use is a green laser line projected onto the floor in front of you. The auditory cue is a metronome,\" she explained. \"So you visualize yourself stepping over that green laser line, stepping to the beat of the metronome. Just by changing the intention behind the movement, by setting that goal, we're changing the part of the brain that's been activated, that allows someone to be able to restore mobility.\"\n\nCollin is happy to see NexStride restoring mobility for people like Hallmark.\n\n\"I am able to walk or take my dog for walks,\" Hallmark said. \"I'm able to get out and go shopping, grocery shopping for my wife -- just do different things like that.\"\n\nThe device is $499 and it's 100% covered for veterans through Veterans Affairs, as well as the Parkinson's Wellness Fund organization.", "extraction_status": "cached"}, {"company": "Partum Health", "title": "Partum Health", "url": "https://medcitynews.com/tag/partum-health/", "source": "MedCity News", "body": "Partum Health, a maternal health startup, recently won the consumer/employer track of the MedCity News INVEST Pitch Perfect contest. The direct-to-consumer company supports families during ...", "date": "2023-06-04", "full_content": "Note: Content could not be properly extracted from this source. Using summary instead.\n\nPartum Health, a maternal health startup, recently won the consumer/employer track of the MedCity News INVEST Pitch Perfect contest. The direct-to-consumer company supports families during ...", "extraction_status": "content_too_short"}, {"company": "Partum Health", "title": "INVEST Pitch Perfect Spotlight: How Partum Health Is Working To Transform Maternal Healthcare", "url": "https://medcitynews.com/2023/06/maternal-healthcare-postpartum-birth-fertility/", "source": "MedCity News", "body": "Meghan Doyle, co-founder and CEO of Partum Health, was working at a consulting firm in the healthcare sector when she first became a mom. It was during this time that she realized how confusing ...", "date": "2023-06-03", "full_content": "Note: Content could not be properly extracted from this source. Using summary instead.\n\nMeghan Doyle, co-founder and CEO of Partum Health, was working at a consulting firm in the healthcare sector when she first became a mom. It was during this time that she realized how confusing ...", "extraction_status": "content_too_short"}, {"company": "Fort Health", "title": "At Fort Health, My Teen Finally Found a Therapist He Doesn't Hate", "url": "https://www.everydayhealth.com/emotional-health/fort-health-review/", "source": "Everyday Health", "body": "Everyday Health independently vets all recommended products. If you purchase a featured product, we may be compensated. Learn why you can trust us. Everyday Health independently vets all ...", "date": "2024-11-18", "full_content": "When you have social anxiety, counseling itself is a form of exposure therapy. My oldest son is 16 and has been dealing with symptoms ofsocial anxietyandobsessive-compulsive disorder (OCD)for about two years. He\u2019s been under the care of a psychiatrist, but none of the online therapy we\u2019ve tried has seemed to stick. Speaking with a counselor adds to his anxiety: On days when he has an appointment, he\u2019ll spend the hours leading up to it stressing and fretting.\n\nHe\u2019s tried two large mainstream online therapy platforms, chosen because he could communicate with the therapist via live chat during sessions or message a therapist without having set appointment times. These services didn\u2019t seem to help him very much, and he never wanted to continue with them for longer than a month or so. Chat and messaging may be less intimidating ways to communicate with a counselor, but they also make it harder for the patient and therapist to get to know each other.\n\n[1]\n\n[2]\n\n[3]\n\nSo, for the sake of this review, I convinced my teen to try Fort Health, even though it only offers more traditional face-to-face video therapy sessions. Fort Health provides online therapy and psychiatry/medication management for people ages 4 to 24 in New York, New Jersey, and Pennsylvania. Caregiver coaching services are also available. We tested Fort Health\u2019s child therapy services for nearly a month. This is how it went.\n\nFort Health\u2019s services are covered by most major insurance plans, including Optum, UnitedHealthcare, Aetna, Cigna, Evernorth, Oxford Health Plans, Horizon BlueCross BlueShield, Geisinger Health Plan, and Humana. Medicaid is not accepted.\n\nOther plans may also be accepted; contact Forth Health customer service to confirm your coverage. If your plan is accepted, you\u2019ll only pay a copay or coinsurance payment. I paid the standard copayment for specialists on my insurance plan, which is $50.\n\nIf paying out of pocket, the company uses the pay-per-appointment model; there are no subscriptions or bundling options. Therapy is $180 for the initial evaluation session and $150 for subsequent 55-minute sessions. Psychiatry is $400 for the initial 60-minute evaluation and $200 for each 30-minute follow-up session. The caregiver coaching course is $149 for two 30-minute sessions and 10 short video lessons. The site asserts that if the caregiver course is undertaken as an addition to your child\u2019s therapy, it may be covered by your insurance plan.\n\nTo sign up for service at Fort Health, I simply clicked on the teal \u201cFind Care Now\u201d button on the homepage. This opens a new tab and begins a series of questions.\n\nFirst it asks who you are seeking care for, with two choices: \u201cI am a caregiver scheduling care for my child\u201d or \u201cI am between 18 and 24, looking for care for myself.\u201d I appreciated this distinction because I\u2019ve signed up for online therapy services for my son before where the platform assumed I was the person seeking care. That meant there was no separate portal for me to log into as a parent, which felt intrusive to my son\u2019s privacy in a way that might hamper his ability to speak freely with the therapist.\n\nNext I was prompted to choose among the three states where Fort Health is available: New York, New Jersey, or Pennsylvania. It also asked me to indicate my child\u2019s age group: child, tween, teen, or young adult. This helped the service match my son with a provider with experience and expertise in the appropriate age group.\n\nSeveral questions ask about what brings your child into therapy. I had the option to choose as many items as applicable from options like school problems, anxiety, depression, attention difficulties, disruptive behavior, grief, unhealthy screen behaviors, sleep issues, trauma, body image, autism, social issues, and substance misuse. It also asks if any of these situations apply to the child within the previous six months: mental health-related hospitalization, suicide attempt, violent behavior resulting in safety concerns for them or others, disordered eating, using someone else\u2019s prescription medication or taking too much of their own medication, having excessive energy to the point of rarely sleeping, or hearing or seeing things others don\u2019t.\n\nThen I was asked whether I was seeking therapy, medication management, or both. At that point, I was able to search for my insurance plan and enter those details. I also submitted a photo of the front and back of my health insurance card so Fort Health could begin the process of confirming my insurance.\n\nI then filled in open-ended questions about my availability. The service needed a time when my son and I were available for an initial therapy evaluation session and for our ongoing weekly availability for a regular session. It explained that my son would attend therapy on his own, so this availability should be his. The service then worked to pair my son with a provider who had an open slot that aligned with my son\u2019s availability so he could continue to have a session at the same time each week.\n\nFinally, I was asked to enter my name, contact information, and preferred communication form and then schedule a time to receive a call from an intake coordinator to book the first appointment and discuss my son\u2019s therapist match. Call slots were available on weekdays at various times between 10 a.m. and 2:45 p.m. as soon as the following business day, but I could also choose to schedule it several weeks or months out if needed. I booked one for within a few days. The entire sign-up process took about 15 minutes.\n\nUpon completion of the sign-up process, I received an email welcoming me to the Fort Health community. It included a link to a short informational video by the company\u2019s clinical director. It also said, \u201cTo get started with care, call this number.\u201d I was a little confused by this since I was told the next step would be to receive a scheduled call from the company, not make a call. I didn\u2019t call the number and was contacted by the intake representative at the scheduled time, so I guess it wasn\u2019t necessary. Still, I appreciated this more personalized email confirmation of signing up for a service consultation.\n\nThe intake coordinator called me promptly at the scheduled time. They were friendly and helpful and seemed happy to answer any questions I had. She said Fort Health had five therapists and two psychiatrists licensed in Pennsylvania and accepting of UnitedHealthcare insurance, though two of these therapists were not accepting new clients at the moment.\n\nShe matched us with a therapist who had ongoing weekly availability during the weekday afternoon time slot I indicated on the sign-up form. The intake coordinator didn\u2019t tell me about her licensure or credentials, and I forgot to ask. Her public profile on the Fort Health site only says she is an LMHC (licensed mental health counselor) and licensed child therapist. Most of the providers advertised on the site are LMHCs, licensed professional counselors (LPCs), or licensed clinical social workers (LCSWs). The site also employs MDs and psychiatric nurse practitioners to provide psychiatry and medication services.\n\n[4]\n\nThe intake coordinator told me she was sending over paperwork that I would need to complete at least 48 hours ahead of the appointment. Appointments are available as late as 7:30 p.m. on weekdays, and client services can be reached until 6:30 p.m. Of course, because this is a child therapy service, afternoon and evening times are highly popular during the school year.\n\nI received an email immediately after this call confirming my appointment for the initial therapy evaluation. There were two big blue buttons to click on to either join the video session or set up our account. I also received an email that our insurance was confirmed.\n\nI then set up our account in the patient portal, filled in the necessary intake paperwork, and input my payment information for copays. I entered my son\u2019s contact and biographical information, such as date of birth, gender, etc. I was pleased to see the diverse gender identification options: Female, Male, Trans Man, Trans Woman, Genderqueer, Other, or Choose Not to Disclose. I then answered a series of open-ended questions about my son\u2019s mental health and medical history, such as any medications he\u2019s currently taking and any previous experience with therapy. I was also asked to share my concerns relating to my son\u2019s mental health. I appreciated that these sections were all fillable boxes rather than multiple choice.\n\nNext, I signed the consent for disclosure for minors form indicating my agreement to allow the therapist to share notes with my son\u2019s primary care provider. This is recommended, but it\u2019s not required. Then came the cancellation policy, which noted that patients who do not cancel at least 48 hours prior to\u00a0their appointment or who do not show up to their appointment will be charged a $90 fee.\n\nFinally came Fort Health\u2019s contact information and virtual therapy guidelines, such as how to help your child prepare for therapy sessions and the importance of them having a dedicated, distraction-free area with a closed door, a computer, and a comfortable chair for the session. The use of phones for attending virtual sessions is discouraged.\n\nMy son said he received a text with a short survey about how he was feeling after I put his information into the intake forms.\n\nBut a few days before the appointment, I got an email and a text saying my appointment may be canceled due to incomplete paperwork. I logged into the portal and looked over the paperwork section. The insurance section said it was marked \u201cskipped\u201d by the intake coordinator since our insurance had already been confirmed. I assumed this was what was triggering the messages. I received no further warnings, and the appointment still existed in the portal as of the day before, so I assumed everything was all set.\n\nFort Health uses the Healthie platform for its user portal. There is no button for logging in to be found on the main Fort Health website, so to make this easier on myself I could either bookmark the Healthie site or log in via one of the emails I had received from Fort Health regarding my appointment. Healthie is available on a desktop browser and as an app.\n\nThe patient portal is essentially the same on a browser or the app. It\u2019s very minimal. I could message the therapist, view or submit paperwork, upload documents, find billing information, edit my account or payment details, do a test video session, view my and my son\u2019s upcoming appointments, and make an appointment. When I clicked on a scheduled appointment, I could reschedule it, cancel it, or join it at the allotted time. The only thing I felt was missing in the portal was the ability to view our therapist\u2019s credentials and bio.\n\nMy son and I both received multiple reminder emails and texts in the days leading up to our appointments to ensure we remembered to attend.\n\nOur initial therapy evaluation appointment, which my son and I both attended, went very well. Our therapist explained treatment expectations at the service and that sessions occur once a week for 55 minutes, with patients attending by phone in case of emergency. She went over the cancellation policy again and noted that more than 10 minutes late was considered a no-show. Subsequent appointments would always be made with the therapist at the end of each session, with the expectation that they would generally be at the same time and day every week.\n\nShe explained that Fort Health uses a shorter-term approach than some other services: A full course of treatment is only expected to last 12 to 20 weeks. In addition, caregivers are expected to attend a 30-minute session with their child\u2019s therapist every two to four weeks. She said this would likely be covered by our insurance and should take place during the daytime hours to save the afternoon and evening slots for children\u2019s appointments.\n\n[5]\n\nThe therapist then asked us about what brought us to therapy. It was clear that she\u2019d read the intake information I\u2019d submitted, which I appreciated. She was very upfront about Fort Health not having any providers who specialized in treating OCD. She even gave us the name of another online service that could help us. Though she assured us that she could help with social anxiety, she understood we may not want to continue with the service because they could not treat OCD. This is something I had never encountered at an online therapy platform before: admission of a lack of specialization and encouragement to seek help elsewhere. I can\u2019t imagine any of the big online therapy platforms doing anything but happily accepting my money.\n\nI said since our insurance was accepted and my son\u2019s biggest issue at the moment was how social anxiety was making school miserable, we would happily try a few sessions.\n\nIn addition to treating all types of anxiety, Fort Health asserts it can help with:\n\nWhile the individual therapy sessions are meant to be between just the child and therapist, my son was nervous, so our therapist assured us I could be there at the beginning to help him transition into the appointment. This was probably the least stressed my son has ever been in a live therapy session. He was comfortable talking to her, which made therapy feel less anxiety-provoking.\n\nHe said the therapist controlled the conversation well and prevented the dreaded awkwardness of long quiet pauses. She was skilled at putting him at ease and helping him be less anxious about talking to a therapist in the first place. She taught him actionable strategies to calm down when he feels those physical symptoms of anxiety start to kick in. These can help prevent him from getting to the point of feeling overwhelmed.\n\nWe scheduled two subsequent sessions at the end of the appointment.\n\nOur second regular session was canceled because the provider was ill. I received a phone call and an email at 9:30 a.m. letting me know that our provider was out sick and our appointment later that afternoon was canceled. While I would\u2019ve preferred we get a make-up session later the same week, I understand that schedules are tight and it likely isn\u2019t possible to reschedule and still fit in a full day of sessions within the next two days.\n\nBecause we\u2019ve had such a good experience with our provider so far, this cancellation didn\u2019t bother me. We still plan to meet with her at the same time next week.\n\nAlso on offer at Fort Health are child psychiatry services and caregiver coaching services. Psychiatrists and psychiatric nurse practitioners at Fort Health can prescribe psychotropic medications appropriate for children via an initial evaluation appointment and regular follow-ups. Caregiver coaching consists of two 30-minute sessions and multiple short educational videos. We did not test these services.\n\nRescheduling upcoming appointments is easy in the Fort Health portal \u2014 as long as your provider has availability within the week that works with your schedule. Otherwise you would likely just cancel your appointment for that week and see your therapist the following week as usual. Since services are charged per appointment and there are no subscriptions, you would simply not make any further appointments with Fort Health to end services. You must cancel or reschedule your appointment with at least 48 hours\u2019 notice, though. The site literally won\u2019t let you cancel or reschedule if it\u2019s less than that. In this case, you can message your provider to reschedule within the week if possible to avoid the cancellation charge.\n\nFort Health is a much smaller operation than many online therapy companies, both in terms of how many providers it employs and the number of states where it\u2019s available. Compared to huge platforms likeTalkspaceorBetterHelp/Teen Counseling(whose teen therapy services we\u2019ve also tried), Fort Health feels very much like a boutique, personalized experience.\n\nBetween the phone call with an intake coordinator and the openness of the therapist about their specialization, Fort Health felt much more like a virtual version of a local therapy office. Still, even though the company is smaller, we still didn\u2019t have to join a waiting list and found a therapist with availability within a week of signing up. When signing up for both Talkspace and BetterHelp, you feel more like just another number than a person. While Talkspace accepted our insurance and offers psychiatry/medication management services, BetterHelp doesn\u2019t accept any insurance and only provides therapy.\n\nBoth Talkspace and BetterHelp can only treat teenagers (age 13 and up), while Fort Health can treat children as young as age 4. Only a few other online therapy services treat children this young. Little Otter treats ages 0 to 14, so it is geared toward the younger crowd: My 16-year-old would be too old. Plus, it\u2019s only available in a few states. LifeStance Health can treat kids of any age and also offers family therapy, but it\u2019s not available nationwide, and therapist availability can vary widely between states.\n\nDoctor On Demandoffers therapy and psychiatry/medication management services to people of all ages and accepts insurance. I like Doctor On Demand: It\u2019s what my son uses for psychiatry, and I have used it for therapy. The providers are caring and professional, and I appreciate that it also has a pay-per-appointment model like Fort Health.Amwellis another platform similar to Doctor On Demand that offers mental and medical care appointments. Amwell can provide therapy to kids as young as age 10. Both Doctor On Demand and Amwell are available nationwide.\n\nI would definitely recommend Fort Health to anyone looking for short-term online mental health services for their child as well as coaching and support for themselves as caregivers. The company serves a wide range of ages, accepts insurance, offers personalized service, and (despite its smaller size) has plenty of provider availability. I really appreciate being able to message with the provider through the patient portal: Therapist messaging isn\u2019t something that\u2019s usually found at these smaller companies. However, I do wish I could see more detailed provider profiles there as well. This would be especially helpful if I was looking to switch providers.\n\nMy son says he has been using the strategies his therapist taught him at school and that he is willing to continue working with this therapist after the testing period. This speaks volumes. Honestly, it\u2019s a small miracle. He usually can\u2019t get me to cancel an online therapy service fast enough and has never found a therapist who has made him feel so at ease about therapy itself and who has offered such concrete, actionable strategies for managing his anxiety. I believe this service can definitely help my son get control of his anxiety and make school more bearable.\n\nThat said, if your child has a diagnosis like OCD or something else outside the company\u2019s stated wheelhouse, it may not be a good fit for you \u2014 and the service will likely advise you of this. It\u2019s also not the service for you if you need a long-term therapy solution. The company considers 12 to 20 weeks of therapy a full course of treatment.\n\nFort Health\u2019s privacy policyis easily accessible and written in plain language instead of legalese. It doesn\u2019t contain anything that alarms me. It states: \u201cWe believe that your health information should have heightened privacy protections, which is also required by federal and state laws. All collection, use, and disclosure of your health information through the Site is governed by Professionals\u2019 Health Information Privacy Policy.\u201d\n\nHere at Everyday Health, we\u2019re testing more than 65 different online therapy companies in order to find the very best ones for your needs. We\u2019re testing them all in the same way \u2014 by doing reporting to vet the company and its business practices, by interviewing and speaking with a dozen different licensed therapists, by surveying real online therapy users, and by testing each service with professional journalists and/or therapists.\n\nTo assess this service, we looked at its quality of care, ease of sign-up, prices, intake process, therapist qualifications, and the user-friendliness of its platform. I am a science journalist and editor with more than 15 years of experience. My articles have appeared inNational Geographic,The Atlantic,New York Magazine,The\u00a0WashingtonPost,Parents,People,SELF, andGood Housekeepingamong others. I\u2019m also aNew York Timesbestselling author of the history booksWomen in White Coats: How the First Women Doctors Changed the World of MedicineandSisters in Science: How Four Women Physicists Escaped Nazi Germany and Made Scientific History. So far I have tested five online therapy platforms.\n\nOlivia Campbell is theNew York Timesbestselling author ofWomen in White Coats: How the First Women Doctors Changed the World of MedicineandSisters in Science: How Four Women Physicists Escaped Nazi Germany and Made Scientific History. She is a freelance editor at Dotdash Meredith and a freelance journalist. Her work has appeared inThe Atlantic,National Geographic,New York Magazine, Health, Parents, History, andThe Guardian, among other outlets.\n\nCampbell received a journalism degree from Virginia Commonwealth University and a master's in science writing from Johns Hopkins University, where she now acts as a thesis advisor. She is a member of the National Association of Science Writers.\n\nCampbell lives outside Philadelphia with her husband, three children, and two cats.", "extraction_status": "cached"}, {"company": "Fort Health", "title": "Fort Health", "url": "https://medcitynews.com/tag/fort-health/", "source": "MedCity News", "body": "Fort Health, a new startup built at Redesign Health, recently launched as a provider of mental healthcare services for children. The company has developed a telehealth-based mental health clinic ...", "date": "2023-02-09", "full_content": "Fort Health's $5.5 million in funding was led by Twelve Below and Vanterra and included participation from Redesign Health, Blue Venture Fund and True Wealth Ventures.", "extraction_status": "cached"}, {"company": "RubyWell", "title": "No news", "url": "", "source": "", "body": "", "date": "2025-06-11", "full_content": "", "extraction_status": "not_attempted"}, {"company": "Atlantic Sea Farms", "title": "Can Small Seaweed Farms Help Kelp Scale Up?", "url": "https://civileats.com/2022/03/16/can-small-seaweed-farms-help-kelp-scale-up/", "source": "Civil Eats", "body": "Atlantic Sea Farms, the first commercial edible seaweed farm in the U.S.\u2014founded in 2006 under the name Ocean Approved\u2014is poised to take advantage of the moment. When Briana Warner, 37, took over as CEO in mid-2018, the Maine-based company was ...", "date": "2022-03-16", "full_content": "While some farms plan to grow massive quantities of kelp, Atlantic Sea Farms is counting on Maine\u2019s small-scale fishermen to expand the industry and distribute ownership.", "extraction_status": "cached"}, {"company": "Atlantic Sea Farms", "title": "With new retail products, Atlantic Sea Farms seeks to expand kelp market", "url": "https://www.mainebiz.biz/article/with-new-retail-products-atlantic-sea-farms-seeks-to-expand-kelp-market", "source": "Mainebiz", "body": "Atlantic Sea Farms A kelp farm can produce three to seven pounds per foot of line. With up to 18,000 feet of line in the water, \"that's a lot of kelp,\" said Atlantic Sea Farms CEO Briana Warner.", "date": "2019-04-17", "full_content": "From left, Atlantic Sea Farms supply chain manager James Crimp, CEO Briana Warner and sales and marketing manager Jesse Baines.", "extraction_status": "cached"}, {"company": "VidaFuel", "title": "Jumpstart Foundry announces 2018 portfolio, brings startups to Nashville", "url": "https://www.bizjournals.com/nashville/news/2018/05/29/jumpstart-foundry-announces-2018-portfolio-brings.html", "source": "The Business Journals", "body": "Jumpstart Foundry brought 13 health care startups to Music City for two days of health care industry networking. Jumpstart Foundry announced its 2018 investment portfolio Tuesday, but the process ...", "date": "2018-05-29", "full_content": "Jumpstart Foundry brought 13 health care startups to Music City for two days of health care industry networking.", "extraction_status": "cached"}, {"company": "VidaFuel", "title": "Vidafuel Nutrition Closes Oversubscribed $1.075 Million Financing to Advance its Clinical Nutrition Brand", "url": "https://www.digitaljournal.com/pr/4861343", "source": "Digital Journal", "body": "Vidafuel, a company developing next-generation clinical nutrition products for use at-home and in the healthcare setting, announced it has closed an oversubscribed $1.075 million financing.", "date": "2020-10-30", "full_content": "Note: Content could not be properly extracted from this source. Using summary instead.\n\nVidafuel, a company developing next-generation clinical nutrition products for use at-home and in the healthcare setting, announced it has closed an oversubscribed $1.075 million financing.", "extraction_status": "content_too_short"}, {"company": "Aloqia", "title": "Shein increases use of deadstock fabric by 40% in 2024", "url": "https://www.msn.com/en-xl/news/other/shein-increases-use-of-deadstock-fabric-by-40-in-2024/ar-AA1CbCXN", "source": "MSN", "body": "Since 2022, Shein has sourced over 47,900 metres of deadstock fabric through Aloqia, leading to estimated savings of 357,600 cubic metres of water, 7,400 kilograms of chemicals, and 70 metric tons ...", "date": "2025-04-03", "full_content": "Note: Content could not be properly extracted from this source. Using summary instead.\n\nSince 2022, Shein has sourced over 47,900 metres of deadstock fabric through Aloqia, leading to estimated savings of 357,600 cubic metres of water, 7,400 kilograms of chemicals, and 70 metric tons ...", "extraction_status": "content_too_short"}, {"company": "Refiberd", "title": "Refiberd scores $200k PDS Ventures investment on GFA Trailblazer win", "url": "https://www.msn.com/en-us/money/technologyinvesting/refiberd-scores-200k-pds-ventures-investment-on-gfa-trailblazer-win/ar-AA1Go12T", "source": "Just Style", "body": "Refiberd has been named the recipient of the Global Fashion Agenda Trailblazer Programme 2025 award, securing an investment of up to $200,000 from PDS Ventures.", "date": "2025-06-09", "full_content": "Note: Content could not be properly extracted from this source. Using summary instead.\n\nRefiberd has been named the recipient of the Global Fashion Agenda Trailblazer Programme 2025 award, securing an investment of up to $200,000 from PDS Ventures.", "extraction_status": "content_too_short"}, {"company": "Refiberd", "title": "Refiberd Wins Trailblazer 2025 With AI-Powered Textile Recycling", "url": "https://www.msn.com/en-us/lifestyle/lifestyle-buzz/refiberd-wins-trailblazer-2025-with-ai-powered-textile-recycling/ar-AA1GeqUb", "source": "Sourcing Journal", "body": "AI-powered textile recycling startup Refiberd won the Global Fashion Agenda's second Trailblazer Programme award.", "date": "2025-06-06", "full_content": "Note: Content could not be properly extracted from this source. Using summary instead.\n\nAI-powered textile recycling startup Refiberd won the Global Fashion Agenda's second Trailblazer Programme award.", "extraction_status": "content_too_short"}, {"company": "Jiminy's", "title": "Pets eat a lot of meat. Insects could lower their carbon pawprint.", "url": "https://grist.org/food/sustainable-cricket-dog-food-jiminys/", "source": "Grist", "body": "Here's How Anne Carlson, the founder and CEO of Jiminy's, discovered this when she began experimenting with bringing insect protein to the pet food industry. She started with cricket treats ...", "date": "2022-09-13", "full_content": "As our climate changes, so will our diets. Fix is exploring that reality through the lens of foods that show what sustainable, equitable, and resilient eating could look like. Try them yourself with the recipes in ourClimate Future Cookbook.\n\nCats and dogs eat a lot of meat. In the U.S., they gobble up abouta quarter of the calories derived from livestock. If they were counted as a country, America\u2019s pets would rank fifth in global meat consumption. Producing all that food generates about \u200b\u200b64 million tons of carbon dioxide a year, not to mention the land, water, and other resources required to farm animals.\n\nAs pet ownership rises,Americans increasingly see their crittersas family members. An ensuing trend toward premium and\u201chuman-grade\u201ddiets has further stressed the carbon-intensive livestock industry. But it also represents a pattern that may bode well for the planet \u2014 pet foodgenerally tends to mirror shiftsin consumer preferences for people, with a growing emphasis on things like health, quality, and sustainability. As eco-friendly alternatives (particularly alternative proteins) establish themselves in our grocery aisles, the pet aisle may not be far behind. One particular ingredient is emerging as a promising option for our furry friends: insects.\n\nInsectshave gotten a lot of attentionin the past decade or so as a mega-efficient, protein-rich superfood of the future. A number of cuisines, particularly in Asia, Africa, and South America, have included insects for thousands of years, but many people remain squeamish about the idea of eating bugs. Dogs don\u2019t have the same hangups.\n\nGrist thanks its sponsors.Become one.\n\nTo support our nonprofit environmental journalism, please considerdisabling your ad-blockerto allow ads on Grist.Here's How\n\nAnne Carlson, the founder and CEO ofJiminy\u2019s, discovered this when she began experimenting with bringing insect protein to the pet food industry. She started with cricket treats \u2014 which dogs went crazy for \u2014 then worked with scientists and veterinarians to determine if crickets and \u201cgrubs,\u201d or black soldier fly larvae, could provide complete nutrition for dogs. Studies showed that they could, and that the bugs also offered an array of compelling health benefits. (Her team is pursuing similar research for cats.) But Carlson was always looking at it from the angle of curbing emissions. For her, it was a personal matter.\n\nIn 2016, after a stint working for a big pet food company, Carlson was pondering her next move. A conversation with her then-college-aged daughter gave Carlson a new outlook on her career when her daughter said she didn\u2019t want to have kids. \u201cHer reason was she was worried about what the world was going to be like by the time they grew up,\u201d Carlson says. \u201cAnd she was talking about climate change.\u201d\n\nCarlson felt a pressing sense of responsibility to be part of creating a world in which her daughter would want to raise children. \u201cI actually decided right then that no matter what I did, it was going to be fighting climate change,\u201d she recalls. She founded Jiminy\u2019s later that year. Today, the company offers dry and wet dog food and treats made of insects; its products are available in around1,400 pet storesnationwide and online through popular retailers like Chewy. Although several other companies now offer insect protein treats, Jiminy\u2019s remains the only company in the U.S. selling bug-based dog food.\n\nWe talked to Carlson about her journey to bring a more sustainable form of protein to the pet market, and what she sees as the future of the industry. Her responses have been edited for length and clarity.\n\nGrist thanks its sponsors.Become one.\n\nTo support our nonprofit environmental journalism, please considerdisabling your ad-blockerto allow ads on Grist.Here's How\n\nQ. Tell me about the Jiminy\u2019s origin story. How did you get the idea to launch an alt-protein company for pets?\n\nA.A little bit after that conversation [with my daughter], I got approached to lead a pet food company. They were framing it as a sustainable alternative for pets. It was grass-fed beef. I absolutely fell in love with this idea of sustainability and pets, but I was like, \u201cYou know what? Cows are never gonna be the answer.\u201d I started thinking, \u201cWhat could be a protein source that would be sustainable for pets? And could it be humane as well?\u201d Because that would be awesome. When you look at traditional protein, it\u2019s pretty terrible from a lot of different perspectives.\n\nI started throwing different types of protein sources onto a page. I actually put an insect on the page. I don\u2019t know why. I don\u2019t know what inspired me to do it, but I kept coming back to it. Then I saw that theU.N. had done a studysaying that insects could be the answer to world hunger.\n\nI ordered roasted crickets online. When I got them, I fed them to my dogs to see what they would do. And the drool started right away. I knew I had something that was gonna work. When you think about a dog \u2014 I don\u2019t know, do you have a dog?\n\nQ. I do!\n\nA.You know if the drool starts, they\u2019re really loving something. And it was flowing freely. Of course, I had to try it, too. I tried the crickets \u2014 and they tasted good! It was a little scary the first time I put it in my mouth, but once you get past that, you\u2019re like, \u201cOh, it tastes like a sunflower seed.\u201d It\u2019s nutty, it\u2019s earthy. We were kind of off to the races at that point.\n\nQ. So you were inspired by the U.N. study about insects as a solution for human diets, and you translated that to pet food. How did that work?\n\nA.We started with the crickets, because they are the easiest to wrap your head around. We like to call them the gateway bug \u2014 but when you look at it, you can see it is a fantastic protein source. It has all of the amino acids that you need to be a complete protein. When you\u2019re working with dogs, you\u2019re looking for 10 essential amino acids, and this delivers it in the quantities that you need. So I knew it was a good protein source, but then you start digging into it and you\u2019re like, \u201cOh, but it also has minerals and vitamins and fiber.\u201d All of these other things make it into even more than just a protein source. It really is a superfood.\n\nAnd what I loved about working with the dogs is that I felt like I could have a huge impact quickly, if I was able to make a food that was complete and balanced that they could eat every day. Because if you think about it, if I were to make something for people \u2014 like, say I make a breakfast bar. Best-case scenario, even if you ate it every single day, I\u2019d only be impacting about 7 percent of your eating occasions. But if I make a food for dogs, I can impact 80 to 90 percent of their eating occasions with one product.\n\nQ. That makes sense. Speaking of the impact, could you give me a quick rundown of some of the benefits of farming insects instead of livestock?\n\nA.You bet. It\u2019s kind of fun, actually. Let me just give you sort of an analogy here: If you had an acre of land and you put cows on it, at the end of a year, you\u2019re gonna get 192 pounds of protein. If you had chickens, you get 265 pounds of protein. But if you had crickets?Sixty-five thousandpounds of protein at the end of the year. And grubs, over a million pounds of protein. [Statistics come from alifecycle assessment by insect producer EnviroFlight.] And there\u2019s a lot of reasons why. They have a shorter lifespan. For crickets, it\u2019s approximately six weeks. They also reproduce at a super-high rate. So if you think about a cow, it\u2019s having one to two babies at a time and it takes nearly a year to gestate, but grubs are laying 500 eggs at a time.\n\n[Read more: Scientists are \u201cmilking\u201d microbes to create cow-free dairy products.]\n\nThe other thing that\u2019s really cool is that there\u2019s no waste. You\u2019re using the entire animal. They\u2019re roasted and ground and the entire animal is used. Even their bedding [and excrement] is used. That\u2019s what they call frass,which is this amazing fertilizer.\n\nQ. Jiminy\u2019s is a pioneer and remains the only U.S. company offering complete-diet dog food made from insect protein. What were some of the challenges getting started?\n\nA.The biggest challenge was proving that it was safe for the dogs. You could look at the nutritional analysis on it, but there was still a question as to whether or not the dogs could actually digest it. We worked with Iowa State andAnimalBiometo doa bunch of studies, and they were all published and peer reviewed. And all of that went into proving that it was safe to use in a food.\n\nWhen we started, we focused on treats. In order to do the food, we had to do all those studies \u2014 we knew it was really important to be able to prove that it was truly digestible and it had utility. And the great news is, what we found is that it is as digestible for dogs as chicken or beef. The other thing we were able to prove is that, because it\u2019s got that fiber that comes from the exoskeleton, that feeds the good bacteria in the dog\u2019s gut. It\u2019s also hypoallergenic \u2014 for dogs that have food allergies, oftentimes this is a great solve for them.\n\nQ. What has been the reaction from pet owners in the five years that Jiminy\u2019s products have been on the market?\n\nA.It\u2019s kind of funny, it\u2019s really shifted. At the beginning, when we would say we\u2019re making dog treats with cricket protein, almost always, it was like, \u201cWait, what?\u201d You\u2019d have to explain that cricket protein is a thing. Now, people are like, \u201cOh, cool, I\u2019ve heard of that!\u201d And sometimes they\u2019ll ask us, \u201cOh, were you onShark Tank?\u201d Because there were a couple of companies making [insect-based] products for peopleonShark Tank\u2014 and we\u2019re like, \u201cNo, that\u2019s not us! But yeah, it\u2019s like that!\u201d\n\nThe other thing that\u2019s really shifted is, during the pandemic, more people adopted pets. And the people who adopted pets had more time to research what they were going to give to their pets \u2013 what kind of food. And one of the other things that\u2019s been happening is pet ownership is starting to shift younger and younger, which is great for us. Millennials and Gen Zare closing in on 50 percent of the pet ownershipin the U.S. \u2014 and they just get it. When we say we\u2019re working with insect protein, they\u2019re like, \u201cThat\u2019s so cool!\u201d And when we talk about the sustainability, they\u2019re like, \u201cYes, that\u2019s important to me.\u201d When we say we\u2019re reducing the carbon pawprint, it just makes sense. They know what we\u2019re talking about.\n\nQ. What\u2019s your vision for where the pet industry could be in 10, 20, or 30 years?\n\nA.It needs to change so much. There needs to be sustainability across the board. I do see some great things that are happening in certain areas. Petco now has this [refill option] for cat litter; you can actually bring your own container and scoop the litter into your own container and take it away, rather than getting another plastic container. I think that\u2019s a great example of innovation in another category within pets. But I\u2019d love to see rethinking of the materials that are used for leashes and collars. I mean, think about going into one of those superstores and how many different types of products there are, and then think about how much plastic there is. We need to get away from these materials that can\u2019t be reused or recycled. And I\u2019d like to see other proteins being used that are sustainable as well \u2014 getting away from the cow and the chicken that is just so problematic.\n\nQ. What about your daughter? Has she shared her thoughts on the company, and how your vision has impacted her?\n\nA.She hasn\u2019t said absolutely that she wants to have kids, but she\u2019s more open to the idea than she was before. I think there\u2019s more hope. She sees what we\u2019re doing, she sees what others are doing. And we\u2019re trying to [approach sustainability] not just from the products that we make, but we\u2019re trying to make sure that everything we do is moving in the right direction. We\u2019re moving our packaging to sustainable packaging. We\u2019re offsetting [our shipping] by planting trees.We planted over 65,000 trees already. Everything that we do, we try to put it through the lens of, is this the best solution? Is this the best answer, when we think about climate change?\n\nRead more from theClimate Future Cookbook:\n\nA message from\n\nGrist is the only award-winning newsroom focused on exploring equitable solutions to climate change. It\u2019s vital reporting made entirely possible by loyal readers like you. At Grist, we don\u2019t believe in paywalls. Instead, we rely on our readers to pitch in what they can so that we can continue bringing you our solution-based climate news.\n\nGrist is the only award-winning newsroom focused on exploring equitable solutions to climate change. It\u2019s vital reporting made entirely possible by loyal readers like you. At Grist, we don\u2019t believe in paywalls. Instead, we rely on our readers to pitch in what they can so that we can continue bringing you our solution-based climate news.\n\nGrist thanks its sponsors.Become one.\n\nGrist thanks its sponsors.Become one.\n\nTo support our nonprofit environmental journalism, please considerdisabling your ad-blockerto allow ads on Grist.Here's How", "extraction_status": "cached"}, {"company": "Jiminy's", "title": "My Dog Loves These Cricket Protein Treats More Than She Loves Me", "url": "https://nymag.com/strategist/article/jiminys-cricket-treats-review.html", "source": "New York Magazine", "body": "That seems more like something you do for a pet snake than a toy poodle. But when a bag of Jiminy's cricket treats were sent to the office by a publicist, I decided to bring them home.", "date": "2020-02-19", "full_content": "MydogUli turns 10 this month. She\u2019s what you call a silver poodle: When she was born, her fur was pitch black, but at around six months, it turned silvery gray, so she\u2019s always kind of looked like she\u2019s equal partspuppyand old lady. Now that she\u2019s gotten old enough to have earned those grays, I have started paying closer attention to the food andtreatsthat I feed her. My hope is that better nutrition will help her live a longer, happier life. For me, this means opting for raw or minimally processeddog foodmade with simple, high-quality ingredients. It also means focusing on what she loves to eat, because the more I think about losing her one day, the more I want to spoil her. Surprisingly, what she loves eating most right now are treats made of crickets.\n\nI don\u2019t know if I would have ever boughtdog treatsmade out of crickets. That seems more like something you do for a pet snake than atoy poodle.But when a bag of Jiminy\u2019s cricket treats were sent to the office by a publicist, I decided to bring themhome. Uli was immediately smitten \u2014 so much so that I\u2019ve bought three more bags in the three months since. With Jiminy\u2019s in front of her, Uli\u2019s priorities shift. Whatever she was doing before, she stops. She\u2019s immediately at attention, barely able to keep her energy in. When I ask her tositor roll over for any othertreat, she does the trick at her normal pace, but the minute she sees (or, more likely, smells) that I am holding a cricket treat, she does a montage of every trick she knows at panicked hyperspeed. These treats are so effective that I\u2019ve been using them to teach her tricks I never would have tried before. (We\u2019re almost at the point where she\u2019ll put her owntoysaway.)\n\nI was curious what effect the treats would have on other dogs \u2014 plus, it\u2019s nice to share the cricket love \u2014 so I gave bags of Jiminy\u2019s to two of my Strategist colleagues who also have small dogs at home. Like Uli, my colleagues\u2019dogs,OakandReggie,took to the cricket treats immediately and with surprising intensity. This was especially unexpected for Oak\u2019s mom, associate director of audience development Stephanie Downes, who says he\u2019s typically a chicken-treat purist. Now, she uses Jiminy\u2019s to get him to take his pills, like delicious little Trojan horses.\n\nCricket treats are higher inproteinand morenutrient densethan beef or chicken treats, and they require fewer resources like land, water, and energy to raise (and cause much lower carbon emissions). I am not a vegetarian, but Iamwary of how much meat I eat and where it comes from, due to the environmental impact, so it makes me feel good to buy dogtreatsmade from more sustainable ingredients. After buying our second bag, my partner and I were so struck by Uli\u2019s obsession with the treats that we decided to taste one. It\u2019s not something we\u2019d serve to guests, but honestly, they taste like health-food-storebeef jerky. And they definitely taste good to Uli, which is the whole point.\n\nThe Strategistis designed to surface the most useful, expert recommendations for things to buy across the vast e-commerce landscape. Some of our latest conquests include the bestacne treatments,rolling luggage,pillows for side sleepers,natural anxiety remedies, andbath towels. We update links when possible, but note that deals can expire and all prices are subject to change.", "extraction_status": "cached"}, {"company": "Aeromutable", "title": "No news", "url": "", "source": "", "body": "", "date": "2025-06-11", "full_content": "", "extraction_status": "not_attempted"}];
        const DEBUG = true;
    
        document.addEventListener('DOMContentLoaded', () => {
            const chatToggle = document.querySelector('.chat-toggle-button');
            const chatContainer = document.querySelector('.chatbot-container');
            const closeChat = document.querySelector('.close-chat');
            const chatInput = document.querySelector('.chatbot-input input');
            const sendButton = document.querySelector('.chatbot-input button');
            const messagesContainer = document.querySelector('.chatbot-messages');
            
            setTimeout(() => {
                chatContainer.classList.add('active');
                chatToggle.style.display = 'none';
                chatInput.focus();
            }, 1000);
            
            chatToggle.addEventListener('click', () => {
                chatContainer.classList.add('active');
                chatToggle.style.display = 'none';
                chatInput.focus();
            });
            
            closeChat.addEventListener('click', () => {
                chatContainer.classList.remove('active');
                setTimeout(() => {
                    chatToggle.style.display = 'flex';
                }, 300);
            });
            
            function sendMessage() {
                const question = chatInput.value.trim();
                if (!question) return;
                
                addMessage(question, 'user');
                chatInput.value = '';
                
                if (handleFollowUp(question)) {
                    return;
                }
                
                conversationState.currentQuery = question;
                conversationState.mode = 'showing_results';
                conversationState.currentArticleIndex = 0;
                processQuery(question);
            }
            
            function addMessage(text, sender) {
                const message = document.createElement('div');
                message.classList.add('message');
                message.classList.add(sender + '-message');
                message.textContent = text;
                messagesContainer.appendChild(message);
                messagesContainer.scrollTop = messagesContainer.scrollHeight;
            }
            
            function addMessageWithCitation(text, citation, url) {
                const messageContainer = document.createElement('div');
                
                const message = document.createElement('div');
                message.classList.add('message');
                message.classList.add('bot-message');
                message.textContent = text;
                
                // Create URL link element if URL is provided
                if (url && url !== "#") {
                    const linkElement = document.createElement('div');
                    linkElement.classList.add('source-link');
                    const link = document.createElement('a');
                    link.href = url;
                    link.target = "_blank"; // Open in new tab
                    link.textContent = url;
                    linkElement.appendChild(link);
                    messageContainer.appendChild(message);
                    messageContainer.appendChild(linkElement);
                } else {
                    // No URL, just add the message
                    messageContainer.appendChild(message);
                }
                
                messagesContainer.appendChild(messageContainer);
                messagesContainer.scrollTop = messagesContainer.scrollHeight;
            }
            
            function processQuery(question) {
                const lowerQuestion = question.toLowerCase();
                
                if (DEBUG) {
                    console.log('Processing query:', question);
                    console.log('Available articles:', newsData.length);
                }
                
                const isCompanyQuery = lowerQuestion.split(' ').length <= 3;
                
                if (isCompanyQuery) {
                    const allCompanies = [...new Set(newsData.map(article => article.company.toLowerCase()))];
                    console.log('All companies:', allCompanies);
                    
                    const exactCompanyMatch = allCompanies.find(company => 
                        company.toLowerCase() === lowerQuestion.trim()
                    );
                    
                    const validPartialMatch = allCompanies.some(company => {
                        const companyWords = company.toLowerCase().split(/\s+/);
                        const queryWords = lowerQuestion.toLowerCase().trim().split(/\s+/);
                        
                        if (company.toLowerCase() === lowerQuestion.toLowerCase().trim()) {
                            return true;
                        }
                        
                        if (company.toLowerCase().includes(lowerQuestion.toLowerCase().trim())) {
                            return true;
                        }
                        
                        if (lowerQuestion.toLowerCase().trim().includes(company.toLowerCase())) {
                            return true;
                        }
                        
                        if (companyWords.length > 1) {
                            if (queryWords.includes(companyWords[0]) && companyWords[0].length > 3) {
                                return true;
                            }
                            
                            const companyPhrase = companyWords.join(' ');
                            const queryPhrase = queryWords.join(' ');
                            
                            for (let i = 0; i < companyWords.length - 1; i++) {
                                const phrase = companyWords[i] + ' ' + companyWords[i+1];
                                if (queryPhrase.includes(phrase)) {
                                    return true;
                                }
                            }
                        }
                        
                        return false;
                    });
                    
                    const companyExists = exactCompanyMatch !== undefined || validPartialMatch;
                    
                    if (!companyExists) {
                        addMessage(`I'm sorry, I don't have any news articles about "${lowerQuestion}". Would you like information about another company?`, 'bot');
                        conversationState.mode = 'initial';
                        return;
                    }
                }
                
                let keywords = [];
                
                const quoteRegex = /"([^"]+)"/g;
                let quoteMatch;
                while ((quoteMatch = quoteRegex.exec(question)) !== null) {
                    keywords.push(quoteMatch[1].toLowerCase());
                }
                
                const stopWords = new Set([
                    'a', 'an', 'the', 'and', 'or', 'but', 'is', 'are', 'was', 'were', 
                    'to', 'of', 'in', 'on', 'at', 'by', 'for', 'with', 'about', 'from',
                    'these', 'those', 'this', 'that', 'have', 'has', 'had', 'do', 'does',
                    'did', 'can', 'could', 'will', 'would', 'should', 'may', 'might'
                ]);
                
                const wordKeywords = lowerQuestion
                    .replace(/[^a-zA-Z0-9 ]/g, ' ')
                    .split(' ')
                    .filter(word => word.length > 2 && !stopWords.has(word.toLowerCase()));
                    
                keywords = [...keywords, ...wordKeywords];
                
                if (DEBUG) {
                    console.log('Extracted keywords:', keywords);
                }
                
                let relevantArticles = [];
                newsData.forEach(article => {
                    let score = 0;
                    const title = article.title.toLowerCase();
                    const body = article.body.toLowerCase();
                    const fullContent = article.full_content ? article.full_content.toLowerCase() : '';
                    const company = article.company.toLowerCase();
                    
                    if (company && lowerQuestion.includes(company)) {
                        score += 15;
                    }
                    
                    if (company && lowerQuestion.trim() === company) {
                        score += 30;
                    }
                    
                    if (company && lowerQuestion.trim().startsWith(company)) {
                        score += 25;
                    }
                    if (company && company.startsWith(lowerQuestion.trim())) {
                        score += 20;
                    }
                    
                    if (isCompanyQuery && company && !company.includes(lowerQuestion) && !lowerQuestion.includes(company)) {
                        const companyFirstWord = company.split(' ')[0].toLowerCase();
                        const queryFirstWord = lowerQuestion.trim().split(' ')[0].toLowerCase();
                        
                        if (companyFirstWord !== queryFirstWord) {
                            score -= 50;
                        }
                    }
                    
                    if (fullContent && fullContent.includes(lowerQuestion)) {
                        score += 10;
                    }
                    
                    keywords.forEach(keyword => {
                        if (company && keyword.length > 2 && company === keyword) {
                            score += 18;
                        }
                        else if (company && keyword.length > 2 && company.includes(keyword)) {
                            score += 5;
                        }
                        if (company && keyword.length > 2 && keyword.includes(company)) {
                            score += 10;
                        }
                        
                        if (title.includes(keyword)) score += 5;
                        if (body.includes(keyword)) score += 3;
                        
                        if (fullContent) {
                            if (keyword.length > 10 && fullContent.includes(keyword)) {
                                score += 8;
                            } else if (fullContent.includes(keyword)) {
                                score += 2;
                            }
                            
                            const keywordRegex = new RegExp(keyword, 'gi');
                            const occurrences = (fullContent.match(keywordRegex) || []).length;
                            score += Math.min(occurrences, 5) * 0.5;
                        }
                    });
                    
                    if (lowerQuestion.includes('who') || lowerQuestion.includes('person')) {
                        const nameRegex = /([A-Z][a-z]+ [A-Z][a-z]+)/g;
                        const names = fullContent ? (fullContent.match(nameRegex) || []) : [];
                        if (names.length > 0) score += 2;
                    }
                    
                    if (score > 0) {
                        if (DEBUG) {
                            console.log(`Article: ${article.title}, Score: ${score}`);
                        }
                        relevantArticles.push({...article, score});
                    }
                });
                
                relevantArticles.sort((a, b) => b.score - a.score);
                
                conversationState.relevantArticles = relevantArticles;
                conversationState.currentArticleIndex = 0;
                
                if (DEBUG) {
                    console.log('Relevant articles found:', relevantArticles.length);
                    if (relevantArticles.length > 0) {
                        console.log('Top article:', relevantArticles[0].title);
                        console.log('Top score:', relevantArticles[0].score);
                    }
                }
                
                if (relevantArticles.length > 0) {
                    const mostRelevant = relevantArticles[0];
                    let response = "";
                    
                    let informativeSnippet = '';
                    if (mostRelevant.full_content) {
                        const fullContent = mostRelevant.full_content;
                        
                        const paragraphs = fullContent.split(/\n+/)
                            .filter(p => p.trim().length > 50);
                        
                        let foundRelevantSnippet = false;
                        for (const paragraph of paragraphs) {
                            const lowerPara = paragraph.toLowerCase();
                            const matchedKeywords = keywords.filter(kw => lowerPara.includes(kw));
                            
                            if (matchedKeywords.length >= 2) {
                                informativeSnippet = paragraph.trim().substring(0, 300) + '...';
                                foundRelevantSnippet = true;
                                break;
                            }
                        }
                        
                        if (!foundRelevantSnippet) {
                            for (const paragraph of paragraphs) {
                                if (keywords.some(keyword => paragraph.toLowerCase().includes(keyword))) {
                                    informativeSnippet = paragraph.trim().substring(0, 300);
                                    foundRelevantSnippet = true;
                                    break;
                                }
                            }
                        }
                        
                        if (!foundRelevantSnippet && fullContent.length > 0) {
                            if (fullContent.length > 500) {
                                const middleStart = Math.floor(fullContent.length / 3);
                                const middleContent = fullContent.substring(middleStart, middleStart + 500);
                                const sentences = middleContent.split(/[.!?] /).filter(s => s.length > 30);
                                
                                if (sentences.length > 0) {
                                    informativeSnippet = sentences[0].trim();
                                } else {
                                    informativeSnippet = fullContent.substring(0, 300);
                                }
                            } else {
                                informativeSnippet = fullContent.substring(0, 300);
                            }
                        }
                    }
                    
                    if (lowerQuestion.includes('what') && lowerQuestion.includes('company')) {
                        response = `${mostRelevant.company}: Based on the news, ${mostRelevant.company} has been mentioned in relation to: "${mostRelevant.title}"`;
                    } else if (lowerQuestion.includes('latest') || lowerQuestion.includes('recent')) {
                        response = `${mostRelevant.company}: The latest news I found is: "${mostRelevant.title}". ${mostRelevant.body.substring(0, 150)}`;
                    } else if (informativeSnippet) {
                        response = `${mostRelevant.company}: ${informativeSnippet}`;
                    } else {
                        response = `${mostRelevant.company}: ${mostRelevant.title} ${mostRelevant.body.substring(0, 150)}`;
                    }
                    
                    addMessageWithCitation(response, `${mostRelevant.source}`, mostRelevant.url);
                    
                    if (relevantArticles.length > 1) {
                        setTimeout(() => {
                            addMessage(`I also found ${relevantArticles.length - 1} more articles that might be relevant. Would you like to know more about any specific topic?`, 'bot');
                            conversationState.mode = 'offering_more';
                        }, 1000);
                    }
                } else {
                    addMessage(`I couldn't find any information about that in the current news articles. Could you try asking something else?`, 'bot');
                    conversationState.mode = 'initial';
                }
            }
            
            const conversationState = {
                mode: 'initial',
                currentQuery: '',
                relevantArticles: [],
                currentArticleIndex: 0
            };
            
            function handleFollowUp(response) {
                const lowerResponse = response.toLowerCase().trim();
                
                if (conversationState.mode === 'offering_more' && 
                    (lowerResponse === 'yes' || lowerResponse === 'sure' || 
                     lowerResponse === 'ok' || lowerResponse.includes('yes'))) {
                    
                    if (conversationState.relevantArticles.length > conversationState.currentArticleIndex + 1) {
                        conversationState.currentArticleIndex++;
                        const nextArticle = conversationState.relevantArticles[conversationState.currentArticleIndex];
                        
                        let response = '';
                        if (nextArticle.full_content) {
                            const snippet = nextArticle.full_content.substring(0, 300);
                            response = `${nextArticle.company}: ${snippet}`;
                        } else {
                            response = `${nextArticle.company}: ${nextArticle.title}. ${nextArticle.body.substring(0, 150)}`;
                        }
                        
                        addMessageWithCitation(response, `${nextArticle.source}`, nextArticle.url);
                        
                        const remaining = conversationState.relevantArticles.length - conversationState.currentArticleIndex - 1;
                        if (remaining > 0) {
                            setTimeout(() => {
                                addMessage(`I have ${remaining} more articles that might interest you. Would you like to see another one?`, 'bot');
                            }, 1000);
                        } else {
                            setTimeout(() => {
                                addMessage(`That's all the relevant articles I found. Is there something else you'd like to know about?`, 'bot');
                                conversationState.mode = 'initial';
                            }, 1000);
                        }
                        return true;
                    }
                }
                
                return false;
            }
            
            sendButton.addEventListener('click', sendMessage);
            chatInput.addEventListener('keypress', (e) => {
                if (e.key === 'Enter') sendMessage();
            });
            
            chatToggle.style.display = 'none';
            chatToggle.style.opacity = '1';
            
            setTimeout(() => {
                chatToggle.classList.add('attention');
            }, 2000);
        });
    
    </script>
</body>
</html>
